(Mark One) | |
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2019 | |
or | |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _______________ to _______________ |
England and Wales | 98-1268150 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
20 Eastbourne Terrace London, United Kingdom | W2 6LG |
(Address of principal executive offices) | (Zip Code) |
(44) (0) 20 3325 0660 | |
Registrant’s telephone number, including area code: |
Securities registered pursuant to Section 12(b) of the Act | ||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Ordinary Shares - £1.00 par value per share | LIVN | NASDAQ Global Market |
Large accelerated filer | þ | Accelerated filer | ¨ |
Non-accelerated filer | ¨ | Smaller reporting company | ¨ |
Emerging growth company | ¨ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act | ¨ |
Class | Outstanding at April 29, 2019 |
Ordinary Shares - £1.00 par value per share | 48,320,894 |
PART I. FINANCIAL INFORMATION | PAGE NO. | |||
PART II. OTHER INFORMATION | ||||
• | Trademarks for our VNS therapy systems, the VNS Therapy® System, the VITARIA® System and our proprietary pulse generator products: Model 102 (Pulse®), Model 102R (Pulse Duo®), Model 103 (Demipulse®), Model 104 (Demipulse Duo®), Model 105 (AspireHC®), Model 106 (AspireSR®) and Model 1000 (SenTiva™). |
• | Trademarks for our Cardiopulmonary product systems: S5® heart-lung machine, S3® heart-lung machine, Inspire™, Heartlink™, XTRA® Autotransfusion System, 3T Heater-Cooler® Connect™ and Revolution®. |
• | Trademarks for our line of surgical tissue and mechanical valve replacements and repair products: Mitroflow®, Crown PRT®, Solo Smart™, Perceval®, Top Hat®, Reduced Series Aortic Valves™, Carbomedics® Carbo-Seal®, Carbo-Seal Valsalva®, Carbomedics® Standard™, Orbis™ and Optiform®, Memo 3D®, Memo 3D® ReChord™, MEMO 4D®, MEMO 4D® ReChord™, AnnuloFlo®, AnnuloFlex®, Bicarbon Slimline™, Bicarbon Filtline™ and Bicarbon Overline®. |
• | changes in our common stock price; |
• | changes in our profitability; |
• | regulatory activities and announcements, including the failure to obtain regulatory approvals for our new products; |
• | effectiveness of our internal controls over financial reporting; |
• | fluctuations in future quarterly operating results; |
• | failure to comply with, or changes in, laws, regulations or administrative practices affecting government regulation of our products, including, but not limited to, U.S. Food and Drug Administration (“FDA”) laws and regulations; |
• | failure to establish, expand or maintain market acceptance of our products for the treatment of our approved indications; |
• | any legislative or administrative reform to the healthcare system, including the U.S. Medicare or Medicaid systems or international reimbursement systems, that significantly reduces reimbursement for our products or procedures or denies coverage for such products or procedures or enhances coverage for competitive products or procedures, as well as adverse decisions by administrators of such systems on coverage or reimbursement issues relating to our products; |
• | failure to maintain the current regulatory approvals for our products’ approved indications; |
• | failure to obtain or maintain coverage and reimbursement for our products’ approved indications; |
• | unfavorable results from clinical studies; |
• | variations in sales and operating expenses relative to estimates; |
• | our dependence on certain suppliers and manufacturers to provide certain materials, components and contract services necessary for the production of our products; |
• | product liability, intellectual property, shareholder-related, environmental-related, income tax and other litigation, disputes, losses and costs; |
• | protection, expiration and validity of our intellectual property; |
• | changes in technology, including the development of superior or alternative technology or devices by competitors; |
• | competition from providers of alternative medical therapies, such as pharmaceutical companies and providers of cannabis; |
• | cyber-attacks or other disruptions to our information technology systems; |
• | failure to comply with applicable U.S. laws and regulations, including federal and state privacy and security laws and regulations; |
• | failure to comply with applicable non-U.S. laws and regulations; |
• | non-U.S. operational and economic risks and concerns; |
• | failure to attract or retain key personnel; |
• | failure of new acquisitions to further our strategic objectives or strengthen our existing businesses; |
• | losses or costs from pending or future lawsuits and governmental investigations; |
• | changes in accounting rules that adversely affect the characterization of our consolidated financial position, results of operations or cash flows; |
• | changes in customer spending patterns; |
• | continued volatility in the global market and worldwide economic conditions, including volatility caused by the implementation of Brexit and/or changes to existing trade agreements and relationships between the U.S. and other countries; |
• | changes in tax laws, including changes related to Brexit, or exposure to additional income tax liabilities; |
• | harsh weather or natural disasters that interrupt our business operations or the business operations of our hospital-customers; and |
• | failure of the market to adopt new therapies or to adopt new therapies quickly. |
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Net sales | $ | 250,801 | $ | 250,398 | ||||
Costs and expenses: | ||||||||
Cost of sales - exclusive of amortization | 84,254 | 84,598 | ||||||
Product remediation | 2,947 | 3,715 | ||||||
Selling, general and administrative | 125,704 | 104,161 | ||||||
Research and development | 43,575 | 31,752 | ||||||
Merger and integration expenses | 3,251 | 2,960 | ||||||
Restructuring expenses | 2,533 | 1,881 | ||||||
Amortization of intangibles | 9,316 | 8,801 | ||||||
Operating (loss) income from continuing operations | (20,779 | ) | 12,530 | |||||
Interest income | 249 | 447 | ||||||
Interest expense | (1,662 | ) | (2,111 | ) | ||||
Gain on acquisition | — | 11,484 | ||||||
Foreign exchange and other gains (losses) | 729 | (273 | ) | |||||
(Loss) income from continuing operations before tax | (21,463 | ) | 22,077 | |||||
Income tax (benefit) expense | (6,614 | ) | 3,893 | |||||
Losses from equity method investments | — | (362 | ) | |||||
Net (loss) income from continuing operations | (14,849 | ) | 17,822 | |||||
Net loss from discontinued operations, net of tax | — | (4,549 | ) | |||||
Net (loss) income | $ | (14,849 | ) | $ | 13,273 | |||
Basic (loss) income per share: | ||||||||
Continuing operations | $ | (0.31 | ) | $ | 0.37 | |||
Discontinued operations | — | (0.10 | ) | |||||
$ | (0.31 | ) | $ | 0.27 | ||||
Diluted (loss) income per share: | ||||||||
Continuing operations | $ | (0.31 | ) | $ | 0.36 | |||
Discontinued operations | — | (0.09 | ) | |||||
$ | (0.31 | ) | $ | 0.27 | ||||
Shares used in computing basic (loss) income per share | 48,246 | 48,324 | ||||||
Shares used in computing diluted (loss) income per share | 48,246 | 49,187 |
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Net (loss) income | $ | (14,849 | ) | $ | 13,273 | |||
Other comprehensive (loss) income: | ||||||||
Net change in unrealized loss on derivatives | (10 | ) | (1,257 | ) | ||||
Tax effect | 2 | 302 | ||||||
Net of tax | (8 | ) | (955 | ) | ||||
Foreign currency translation adjustment, net of tax | (4,229 | ) | 10,553 | |||||
Total other comprehensive (loss) income | (4,237 | ) | 9,598 | |||||
Total comprehensive (loss) income | $ | (19,086 | ) | $ | 22,871 |
March 31, 2019 | December 31, 2018 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 50,776 | $ | 47,204 | ||||
Accounts receivable, net of allowance of $11,484 at March 31, 2019 and $11,598 at December 31, 2018 | 247,059 | 256,135 | ||||||
Inventories | 161,267 | 153,535 | ||||||
Prepaid and refundable taxes | 47,225 | 46,852 | ||||||
Prepaid expenses and other current assets | 34,275 | 29,571 | ||||||
Total Current Assets | 540,602 | 533,297 | ||||||
Property, plant and equipment, net | 185,947 | 191,400 | ||||||
Goodwill | 952,117 | 956,815 | ||||||
Intangible assets, net | 758,528 | 770,439 | ||||||
Operating lease assets (Note 10) | 57,070 | — | ||||||
Investments | 24,762 | 24,823 | ||||||
Deferred tax assets | 74,876 | 68,146 | ||||||
Other assets | 5,642 | 4,781 | ||||||
Total Assets | $ | 2,599,544 | $ | 2,549,701 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Current debt obligations | $ | 39,442 | $ | 28,794 | ||||
Accounts payable | 80,199 | 76,735 | ||||||
Accrued liabilities and other | 150,536 | 124,285 | ||||||
Current litigation provision liability | 252,051 | 161,851 | ||||||
Taxes payable | 9,834 | 22,530 | ||||||
Accrued employee compensation and related benefits | 90,248 | 82,551 | ||||||
Total Current Liabilities | 622,310 | 496,746 | ||||||
Long-term debt obligations | 141,850 | 139,538 | ||||||
Contingent consideration | 147,080 | 161,381 | ||||||
Litigation provision liability | 42,000 | 132,210 | ||||||
Deferred tax liabilities | 73,143 | 68,189 | ||||||
Long-term operating lease liabilities (Note 10) | 47,227 | — | ||||||
Long-term employee compensation and related benefits | 22,551 | 25,264 | ||||||
Other long-term liabilities | 16,577 | 22,635 | ||||||
Total Liabilities | 1,112,738 | 1,045,963 | ||||||
Commitments and contingencies (Note 11) | ||||||||
Stockholders’ Equity: | ||||||||
Ordinary Shares, £1.00 par value: unlimited shares authorized; 49,329,119 shares issued and 48,318,226 shares outstanding at March 31, 2019; 49,323,418 shares issued and 48,205,783 shares outstanding at December 31, 2018 | 76,151 | 76,144 | ||||||
Additional paid-in capital | 1,707,117 | 1,705,111 | ||||||
Accumulated other comprehensive loss | (28,713 | ) | (24,476 | ) | ||||
Accumulated deficit | (266,428 | ) | (251,579 | ) | ||||
Treasury stock at cost, 1,010,893 shares at March 31, 2019 and 1,117,635 shares at December 31, 2018 | (1,321 | ) | (1,462 | ) | ||||
Total Stockholders’ Equity | 1,486,806 | 1,503,738 | ||||||
Total Liabilities and Stockholders’ Equity | $ | 2,599,544 | $ | 2,549,701 |
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Operating Activities: | ||||||||
Net (loss) income | $ | (14,849 | ) | $ | 13,273 | |||
Non-cash items included in net (loss) income: | ||||||||
Depreciation | 7,547 | 8,334 | ||||||
Amortization | 9,316 | 8,802 | ||||||
Stock-based compensation | 6,872 | 6,680 | ||||||
Deferred tax expense (benefit) | 1,993 | (922 | ) | |||||
Losses from equity method investments | — | 1,573 | ||||||
Gain on acquisition | — | (11,484 | ) | |||||
Amortization of income taxes payable on inter-company transfers of property | 1,411 | 1,979 | ||||||
Remeasurement of contingent consideration to fair value | 9,457 | 673 | ||||||
Other | 3,354 | (1,230 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 7,064 | 9,109 | ||||||
Inventories | (8,292 | ) | (6,305 | ) | ||||
Other current and non-current assets | (23,377 | ) | (16,691 | ) | ||||
Accounts payable and accrued current and non-current liabilities | 6,384 | 5,697 | ||||||
Restructuring reserve | (4,906 | ) | 905 | |||||
Net cash provided by operating activities | 1,974 | 20,393 | ||||||
Investing Activities: | ||||||||
Acquisition, net of cash acquired | — | (77,629 | ) | |||||
Purchases of property, plant and equipment and other | (5,741 | ) | (5,846 | ) | ||||
Proceeds from asset sales | 100 | 123 | ||||||
Net cash used in investing activities | (5,641 | ) | (83,352 | ) | ||||
Financing Activities: | ||||||||
Change in short-term borrowing, net | 11,061 | 15,503 | ||||||
Proceeds from short-term borrowing (maturities greater than 90 days) | — | 20,000 | ||||||
Proceeds from long-term debt obligations | 2,973 | — | ||||||
Proceeds from exercise of stock options | 119 | 1,607 | ||||||
Debt issuance costs | (1,750 | ) | — | |||||
Shares repurchased from employees for minimum tax withholding | (4,606 | ) | (4,919 | ) | ||||
Other | (208 | ) | (144 | ) | ||||
Net cash provided by financing activities | 7,589 | 32,047 | ||||||
Effect of exchange rate changes on cash and cash equivalents | (350 | ) | 2,261 | |||||
Net increase (decrease) in cash and cash equivalents | 3,572 | (28,651 | ) | |||||
Cash and cash equivalents at beginning of period | 47,204 | 93,615 | ||||||
Cash and cash equivalents at end of period | $ | 50,776 | $ | 64,964 |
Cash | $ | 78,332 | ||
Contingent consideration | 112,744 | |||
Fair value of our interest in ImThera prior to the acquisition (1) | 25,580 | |||
Fair value of consideration transferred | $ | 216,656 |
(1) | The fair value of our previously-held interest in ImThera was determined based on the fair value of total consideration transferred and application of a discount for lack of control. As a result, we recognized a gain of $11.5 million for the fair value in excess of our carrying value of $14.1 million. The gain is included in gain on acquisition on our condensed consolidated statement of income for the three months ended March 31, 2018. |
Initial Purchase Price Allocation | Measurement Period Adjustments (1) | Adjusted Purchase Price Allocation | ||||||||||
In-process research and development (2) | $ | 151,605 | $ | 10,677 | $ | 162,282 | ||||||
Developed technology | 5,661 | (5,661 | ) | — | ||||||||
Goodwill | 87,063 | (4,467 | ) | 82,596 | ||||||||
Deferred tax liabilities, net (3) | (27,980 | ) | (1,278 | ) | (29,258 | ) | ||||||
Other assets and liabilities, net | 836 | 200 | 1,036 | |||||||||
Net assets acquired | $ | 217,185 | $ | (529 | ) | $ | 216,656 |
(1) | During the second quarter of 2018, measurement period adjustments were recorded based upon new information obtained about facts and circumstances that existed as of the acquisition date. |
(2) | The fair value of in-process research and development ("IPR&D") was determined using the income approach, which is a valuation technique that provides a fair value estimate based on the market participant expectations of cash flows the asset would generate. The cash flows were discounted commensurate with the level of risk associated with the asset. The discount rates were developed after assigning a probability of success to achieving the projected cash flows based on the current stage of development, inherent uncertainty in reaching certain regulatory milestones and risks associated with commercialization of the product. The IPR&D amount is included in intangible assets, net on the condensed consolidated balance sheets at March 31, 2019 and December 31, 2018. |
(3) | The amounts are presented net of deferred tax assets acquired. |
ImThera Acquisition | Fair value at January 16, 2018 | Valuation Technique | Unobservable Input | Ranges | ||||||
Regulatory milestone-based payment | $ | 50,429 | Discounted cash flow | Discount rate | 4.3% - 4.7% | |||||
Probability of payment | 85% - 95% | |||||||||
Projected payment years | 2020 - 2021 | |||||||||
Sales-based earnout | 62,315 | Monte Carlo simulation | Risk-adjusted discount rate | 11.5% | ||||||
Credit risk discount rate | 4.7% - 5.8% | |||||||||
Revenue volatility | 29.3% | |||||||||
Probability of payment | 85% - 95% | |||||||||
Projected years of earnout | 2020 - 2025 | |||||||||
$ | 112,744 |
Cash | $ | 203,671 | ||
Contingent consideration | 40,190 | |||
Fair value of consideration transferred | $ | 243,861 |
Initial Purchase Price Allocation | Measurement Period Adjustments (1) | Adjusted Purchase Price Allocation | ||||||||||
In-process research and development (2) (3) | $ | 110,977 | $ | (3,474 | ) | $ | 107,503 | |||||
Trade names (2) | 11,539 | — | 11,539 | |||||||||
Developed technology (2) | 6,387 | — | 6,387 | |||||||||
Goodwill | 118,917 | (797 | ) | 118,120 | ||||||||
Inventory | 10,296 | (140 | ) | 10,156 | ||||||||
Other assets and liabilities, net | 3,632 | 242 | 3,874 | |||||||||
Deferred tax liabilities, net | (17,887 | ) | 4,169 | (13,718 | ) | |||||||
Net assets acquired | $ | 243,861 | $ | — | $ | 243,861 |
(1) | During the third quarter of 2018, measurement period adjustments were recorded based upon new information regarding future estimates of R&D expenses that existed as of the acquisition date. In addition, during the first quarter of 2019, measurement period adjustments related to finalizing our tax attributes were recorded, which resulted in an increase of $3.3 million in deferred tax assets and a commensurate decrease to goodwill. |
(2) | The amounts are included in intangible assets, net in the condensed consolidated balance sheets at March 31, 2019 and December 31, 2018. Trade names and developed technology are amortized over remaining useful lives of 15 and 2 years, respectively. |
(3) | The fair value of IPR&D was determined using the income approach, which is a valuation technique that provides a fair value estimate based on the market participant expectations of cash flows the asset would generate. The cash flows were discounted commensurate with the level of risk associated with the asset. The discount rates were developed after assigning a probability of success to achieving the projected cash flows based on the current stage of development, inherent uncertainty in reaching certain regulatory milestones and risks associated with commercialization of the product. |
TandemLife Acquisition | Fair value at April 4, 2018 | Valuation Technique | Unobservable Input | Ranges | ||||||
Regulatory milestone-based payments | $ | 40,190 | Discounted cash flow | Discount rate | 4.2% - 4.8% | |||||
Probability of payments | 75% - 95% | |||||||||
Projected payment years | 2019 - 2020 |
Three Months Ended March 31, 2018 | |||
Net sales | $ | 60,107 | |
Costs and expenses: | |||
Cost of sales | 22,138 | ||
Selling, general and administrative expenses | 31,826 | ||
Research and development | 11,281 | ||
Restructuring expenses | 651 | ||
Revaluation gain on assets and liabilities held for sale | (1,213 | ) | |
Operating loss from discontinued operations | (4,576 | ) | |
Foreign exchange and other gains | 79 | ||
Loss from discontinued operations, before tax | (4,497 | ) | |
Income tax benefit | (1,159 | ) | |
Losses from equity method investments | (1,211 | ) | |
Net loss from discontinued operations | $ | (4,549 | ) |
Employee Severance and Other Termination Costs | Other | Total | ||||||||||
Balance at December 31, 2018 | $ | 10,195 | $ | 3,069 | $ | 13,264 | ||||||
Charges | 2,480 | 53 | 2,533 | |||||||||
Cash payments and other | (7,289 | ) | (2,945 | ) | (10,234 | ) | ||||||
Balance at March 31, 2019 | $ | 5,386 | $ | 177 | $ | 5,563 |
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Cardiovascular | $ | 422 | $ | 1,341 | ||||
Neuromodulation | 432 | 6 | ||||||
Other | 1,679 | 534 | ||||||
Total | $ | 2,533 | $ | 1,881 |
Balance at December 31, 2018 | $ | 14,745 | ||
Adjustments | 589 | |||
Remediation activity | (3,582 | ) | ||
Effect of changes in foreign currency exchange rates | (231 | ) | ||
Balance at March 31, 2019 (1) | $ | 11,521 |
(1) | At March 31, 2019, the product remediation liability balance is included within accrued liabilities and other on the condensed consolidated balance sheet. |
March 31, 2019 | December 31, 2018 | |||||||
Respicardia Inc. (1) | $ | 17,706 | $ | 17,706 | ||||
Ceribell, Inc. | 3,000 | 3,000 | ||||||
Rainbow Medical Ltd. | 1,099 | 1,119 | ||||||
MD Start II | 1,123 | 1,144 | ||||||
Highlife S.A.S. | 1,064 | 1,084 | ||||||
Other | 770 | 770 | ||||||
$ | 24,762 | $ | 24,823 |
(1) | Respicardia Inc. (“Respicardia”) is a privately funded U.S. company developing an implantable device designed to restore a more natural breathing pattern during sleep in patients with central sleep apnea by transvenously stimulating the phrenic nerve. We have a loan outstanding to Respicardia, with a carrying amount of $0.6 million as of March 31, 2019 and December 31, 2018, which is included in prepaid expenses and other current assets in the condensed consolidated balance sheet. |
Fair Value as of March 31, 2019 | Fair Value Measurements Using Inputs Considered as: | |||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||
Assets: | ||||||||||||||||
Derivative assets - freestanding instruments (foreign currency exchange rate “FX”) | $ | 228 | $ | — | $ | 228 | $ | — | ||||||||
$ | 228 | $ | — | $ | 228 | $ | — | |||||||||
Liabilities: | ||||||||||||||||
Derivative liabilities - designated as cash flow hedges FX | $ | 1,082 | $ | — | $ | 1,082 | $ | — | ||||||||
Derivative liabilities - designated as cash flow hedges (interest rate swaps) | 738 | — | 738 | — | ||||||||||||
Derivative liabilities - freestanding instruments FX | 198 | — | 198 | — | ||||||||||||
Contingent consideration (1) | 189,382 | — | — | 189,382 | ||||||||||||
$ | 191,400 | $ | — | $ | 2,018 | $ | 189,382 |
Fair Value as of December 31, 2018 | Fair Value Measurements Using Inputs Considered as: | |||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||
Assets: | ||||||||||||||||
Derivative assets - freestanding instruments (foreign currency exchange rate "FX") | $ | 236 | $ | — | $ | 236 | $ | — | ||||||||
$ | 236 | $ | — | $ | 236 | $ | — | |||||||||
Liabilities: | ||||||||||||||||
Derivative liabilities - designated as cash flow hedges (FX) | $ | 1,354 | $ | — | $ | 1,354 | $ | — | ||||||||
Derivative liabilities - designated as cash flow hedges (interest rate swaps) | 865 | — | 865 | — | ||||||||||||
Derivative liabilities - freestanding instruments (FX) | 3,173 | — | 3,173 | — | ||||||||||||
Contingent consideration (1) | 179,911 | — | — | 179,911 | ||||||||||||
$ | 185,303 | $ | — | $ | 5,392 | $ | 179,911 |
(1) | The contingent consideration liability represents contingent payments related to four completed acquisitions: Inversiones Drilltex SAS (“Drillex”), Caisson, ImThera and TandemLife. See the table below for additional information. |
Total contingent consideration liability at December 31, 2018 | $ | 179,911 | ||
Changes in fair value (1) | 9,457 | |||
Effect of changes in foreign currency exchange rates | 14 | |||
Total contingent consideration liability at March 31, 2019 | 189,382 | |||
Less current portion of contingent consideration liability at March 31, 2019 | 42,302 | |||
Long-term portion of contingent consideration liability at March 31, 2019 | $ | 147,080 |
(1) | The change in fair value was primarily due to the impact of decreases in interest rates subsequent to December 31, 2018, which directly impacts the discount rate utilized in the valuation of contingent consideration. |
March 31, 2019 | December 31, 2018 | Maturity | Interest Rate | ||||||||||
2017 European Investment Bank (1) | $ | 103,570 | $ | 103,570 | June 2026 | 3.59 | % | ||||||
2014 European Investment Bank (2) | 46,745 | 47,606 | June 2021 | 0.97 | % | ||||||||
Mediocredito Italiano (3) | 7,502 | 7,623 | December 2023 | 0.50% - 3.02% | |||||||||
Bank of America, U.S. | 2,973 | — | January 2021 | 4.51 | % | ||||||||
Banca del Mezzogiorno (4) | 2,678 | 2,718 | December 2019 | 0.50% - 3.07% | |||||||||
Region Wallonne | 719 | 742 | December 2023 and June 2033 | 0.75% - 1.24% | |||||||||
Mediocredito Italiano - mortgages and other | 543 | 582 | September 2021 and September 2026 | 0.77% - 1.27% | |||||||||
Total long-term facilities | 164,730 | 162,841 | |||||||||||
Less current portion of long-term debt | 22,880 | 23,303 | |||||||||||
Total long-term debt | $ | 141,850 | $ | 139,538 |
(1) | The 2017 European Investment Bank (“2017 EIB”) loan was obtained to support certain product development projects. The interest rate for the 2017 EIB loan is reset by the lender each principal payment date based on LIBOR. Interest payments are paid quarterly and principal payments are paid semi-annually. |
(2) | The 2014 European Investment Bank (“2014 EIB”) loan was obtained in July 2014 to support certain product development projects. The interest rate for the 2014 EIB loan is reset by the lender each quarter based on the Euribor. Interest payments are paid quarterly and principal payments are paid semi-annually. |
(3) | We obtained the Mediocredito Italiano Bank loan in July 2016 as part of the Fondo Innovazione Teconologica program implemented by the Italian Ministry of Education. |
(4) | The Banca del Mezzogiorno loan was obtained in January 2015 to support R&D projects as a part of the Large Strategic Project program of the Italian Ministry of Education. |
Description of Derivative Contract | March 31, 2019 | December 31, 2018 | ||||||
FX derivative contracts to be exchanged for British Pounds | $ | 7,176 | $ | 9,629 | ||||
FX derivative contracts to be exchanged for Japanese Yen | 21,932 | 23,985 | ||||||
FX derivative contracts to be exchanged for Canadian Dollars | 5,301 | 7,637 | ||||||
FX derivative contracts to be exchanged for Euros | 19,574 | 29,768 | ||||||
Interest rate swap contracts | 37,422 | 38,115 | ||||||
$ | 91,405 | $ | 109,134 |
Description of Derivative Contract | After-tax net loss in AOCI as of March 31, 2019 | Amount Expected to be Reclassified to Earnings in Next 12 Months | ||||||
FX derivative contracts | $ | (805 | ) | $ | (805 | ) | ||
Interest rate swap contracts | (147 | ) | (66 | ) | ||||
$ | (952 | ) | $ | (871 | ) |
Three Months Ended March 31, | ||||||||||||||||||
2019 | 2018 | |||||||||||||||||
Description of Derivative Contract | Location in Earnings of Reclassified Gain or Loss | Gains Recognized in OCI | Gains (Losses) Reclassified from AOCI to Earnings | Gains Recognized in OCI | Gains Reclassified from AOCI to Earnings | |||||||||||||
FX derivative contracts | Foreign exchange and other gains | $ | 1,309 | $ | 1,642 | $ | 214 | $ | 846 | |||||||||
FX derivative contracts | SG&A | — | (310 | ) | — | 625 | ||||||||||||
Interest rate swap contracts | Interest expense | — | (13 | ) | — | — | ||||||||||||
$ | 1,309 | $ | 1,319 | $ | 214 | $ | 1,471 |
March 31, 2019 | Asset Derivatives | Liability Derivatives | ||||||||||
Derivatives Designated as Hedging Instruments | Balance Sheet Location | Fair Value (1) | Balance Sheet Location | Fair Value (1) | ||||||||
Interest rate swap contracts | Prepaid expenses and other current assets | $ | — | Accrued liabilities | $ | 479 | ||||||
Interest rate swap contracts | Other assets | — | Other long-term liabilities | 259 | ||||||||
FX derivative contracts | Prepaid expenses and other current assets | — | Accrued liabilities | 1,082 | ||||||||
Total derivatives designated as hedging instruments | — | 1,820 | ||||||||||
Derivatives Not Designated as Hedging Instruments | ||||||||||||
FX derivative contracts | Prepaid expenses and other current assets | 228 | Accrued liabilities | 198 | ||||||||
Total derivatives not designated as hedging instruments | 228 | 198 | ||||||||||
Total derivatives | $ | 228 | $ | 2,018 |
December 31, 2018 | Asset Derivatives | Liability Derivatives | ||||||||||
Derivatives Designated as Hedging Instruments | Balance Sheet Location | Fair Value (1) | Balance Sheet Location | Fair Value (1) | ||||||||
Interest rate swap contracts | Prepaid expenses and other current assets | $ | — | Accrued liabilities | $ | 536 | ||||||
Interest rate swap contracts | Other assets | — | Other long-term liabilities | 329 | ||||||||
FX derivative contracts | Prepaid expenses and other current assets | — | Accrued liabilities | 1,354 | ||||||||
Total derivatives designated as hedging instruments | — | 2,219 | ||||||||||
Derivatives Not Designated as Hedging Instruments | ||||||||||||
FX derivative contracts | Prepaid expenses and other current assets | 236 | Accrued liabilities | 3,173 | ||||||||
Total derivatives not designated as hedging instruments | 236 | 3,173 | ||||||||||
Total derivatives | $ | 236 | $ | 5,392 |
(1) | For the classification of inputs used to evaluate the fair value of our derivatives, refer to “Note 7. Fair Value Measurements.” |
Operating Lease Assets and Liabilities | March 31, 2019 | |||
Assets | ||||
Operating lease right-of-use assets | $ | 57,070 | ||
Liabilities | ||||
Accrued liabilities and other | $ | 10,779 | ||
Long-term operating lease liabilities | 47,227 | |||
Total lease liabilities | $ | 58,006 |
Operating Lease Cost | Three Months Ended March 31, 2019 | |||
Operating lease cost | $ | 3,740 | ||
Variable lease cost | 171 | |||
Short-term lease cost | 86 | |||
Total lease cost | $ | 3,997 |
2019 | $ | 8,790 | ||
2020 | 10,428 | |||
2021 | 8,557 | |||
2022 | 7,499 | |||
2023 | 6,463 | |||
Thereafter | 22,095 | |||
Total lease payments | 63,832 | |||
Less: Amount representing interest | 5,826 | |||
Present value of lease liabilities | $ | 58,006 |
Lease Term and Discount Rate | March 31, 2019 | ||
Weighted Average Remaining Lease Term | 7.7 | ||
Weighted Average Discount Rate | 2.3 | % |
Other Information (in thousands) | Three Months Ended March 31, 2019 | |||
Cash paid for amounts included in the measurement of lease liabilities: | ||||
Operating cash flows for leases | $ | 3,842 | ||
Operating lease assets obtained in exchange for lease liabilities | $ | 465 |
Less than one year | $ | 11,986 | ||
One to three years | 21,031 | |||
Three to five years | 14,998 | |||
Thereafter | 20,943 | |||
Total | $ | 68,958 |
Ordinary Shares | Ordinary Shares - Amount | Additional Paid-In Capital | Treasury Stock | Accumulated Other Comprehensive (Loss) Income | Retained Deficit | Total Stockholders' Equity | |||||||||||||||||||||
December 31, 2018 | 49,323 | $ | 76,144 | $ | 1,705,111 | $ | (1,462 | ) | $ | (24,476 | ) | $ | (251,579 | ) | $ | 1,503,738 | |||||||||||
Stock-based compensation plans | 6 | 7 | 2,006 | 141 | — | — | 2,154 | ||||||||||||||||||||
Net loss | — | — | — | — | — | (14,849 | ) | (14,849 | ) | ||||||||||||||||||
Other comprehensive loss | — | — | — | — | (4,237 | ) | — | (4,237 | ) | ||||||||||||||||||
March 31, 2019 | 49,329 | $ | 76,151 | $ | 1,707,117 | $ | (1,321 | ) | $ | (28,713 | ) | $ | (266,428 | ) | $ | 1,486,806 | |||||||||||
December 31, 2017 | 48,290 | $ | 74,750 | $ | 1,735,048 | $ | (133 | ) | $ | 45,313 | $ | (39,664 | ) | $ | 1,815,314 | ||||||||||||
Adoption of ASU No. 2016-16 | — | — | — | — | — | (22,430 | ) | (22,430 | ) | ||||||||||||||||||
Share issuances | 300 | 422 | — | (422 | ) | — | — | — | |||||||||||||||||||
Stock-based compensation plans | 38 | 52 | 2,996 | 180 | — | — | 3,228 | ||||||||||||||||||||
Net income | — | — | — | — | — | 13,273 | 13,273 | ||||||||||||||||||||
Other comprehensive income | — | — | — | — | 9,597 | — | 9,597 | ||||||||||||||||||||
March 31, 2018 | 48,628 | $ | 75,224 | $ | 1,738,044 | $ | (375 | ) | $ | 54,910 | $ | (48,821 | ) | $ | 1,818,982 |
Change in Unrealized Gain (Loss) on Derivatives | Foreign Currency Translation Adjustments Gain (Loss) (1) | Total | ||||||||||
As of December 31, 2018 | $ | (944 | ) | $ | (23,532 | ) | $ | (24,476 | ) | |||
Other comprehensive income (loss) before reclassifications, before tax | 1,309 | (4,229 | ) | (2,920 | ) | |||||||
Tax expense | (314 | ) | — | (314 | ) | |||||||
Other comprehensive income (loss) before reclassifications, net of tax | 995 | (4,229 | ) | (3,234 | ) | |||||||
Reclassification of gain from accumulated other comprehensive income (loss), before tax | (1,319 | ) | — | (1,319 | ) | |||||||
Reclassification of tax expense | 316 | — | 316 | |||||||||
Reclassification of gain from accumulated other comprehensive income (loss), after tax | (1,003 | ) | — | (1,003 | ) | |||||||
Net current-period other comprehensive loss, net of tax | (8 | ) | (4,229 | ) | (4,237 | ) | ||||||
As of March 31, 2019 | $ | (952 | ) | $ | (27,761 | ) | $ | (28,713 | ) | |||
As of December 31, 2017 | $ | (919 | ) | $ | 46,232 | $ | 45,313 | |||||
Other comprehensive income before reclassifications, before tax | 214 | 10,552 | 10,766 | |||||||||
Tax benefit | (51 | ) | — | (51 | ) | |||||||
Other comprehensive income before reclassifications, net of tax | 163 | 10,552 | 10,715 | |||||||||
Reclassification of gain from accumulated other comprehensive income, before tax | (1,471 | ) | — | (1,471 | ) | |||||||
Reclassification of tax benefit | 353 | — | 353 | |||||||||
Reclassification of gain from accumulated other comprehensive income, after tax | (1,118 | ) | — | (1,118 | ) | |||||||
Net current-period other comprehensive (loss) income, net of tax | (955 | ) | 10,552 | 9,597 | ||||||||
As of March 31, 2018 | $ | (1,874 | ) | $ | 56,784 | $ | 54,910 |
(1) | Taxes are not provided for foreign currency translation adjustments as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned. |
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Service-based restricted stock units ("RSUs") | $ | 2,970 | $ | 2,156 | ||||
Service-based stock appreciation rights ("SARs") | 2,008 | 1,348 | ||||||
Market performance-based restricted stock units | 551 | 345 | ||||||
Operating performance-based restricted stock units | 971 | 848 | ||||||
Employee stock purchase plan | 372 | — | ||||||
Total stock-based compensation expense | $ | 6,872 | $ | 4,697 |
Three Months Ended March 31, 2019 | |||||||
Shares | Weighted Average Grant Date Fair Value | ||||||
Service-based SARs | 577 | $ | 31.40 | ||||
Service-based RSUs | 234 | $ | 97.25 | ||||
Market performance-based RSUs | 43 | $ | 101.10 | ||||
Operating performance-based RSUs | 43 | $ | 97.25 |
Three Months Ended March 31, | ||||||
2019 | 2018 | |||||
Basic weighted average shares outstanding | 48,246 | 48,324 | ||||
Add effects of share-based compensation instruments (1) | — | 863 | ||||
Diluted weighted average shares outstanding | 48,246 | 49,187 |
(1) | Excluded from the computation of diluted earnings per share for the three months ended March 31, 2019 and March 31, 2018 were stock options, SARs and restricted share units totaling 3.3 million and 0.8 million, because to include them would have been anti-dilutive under the treasury stock method. |
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Cardiopulmonary | ||||||||
United States | $ | 39,123 | $ | 38,445 | ||||
Europe | 35,561 | 36,870 | ||||||
Rest of world | 46,886 | 49,815 | ||||||
121,570 | 125,130 | |||||||
Heart Valves | ||||||||
United States | 4,356 | 6,536 | ||||||
Europe | 10,513 | 12,116 | ||||||
Rest of world | 10,804 | 12,390 | ||||||
25,673 | 31,042 | |||||||
Advanced Circulatory Support | ||||||||
United States | 8,033 | — | ||||||
Europe | 119 | — | ||||||
Rest of world | 96 | — | ||||||
8,248 | — | |||||||
Cardiovascular | ||||||||
United States | 51,512 | 44,981 | ||||||
Europe | 46,193 | 48,986 | ||||||
Rest of world | 57,786 | 62,205 | ||||||
155,491 | 156,172 | |||||||
Neuromodulation | ||||||||
United States | 76,886 | 77,992 | ||||||
Europe | 10,659 | 10,291 | ||||||
Rest of world | 7,104 | 5,561 | ||||||
94,649 | 93,844 | |||||||
Other | 661 | 382 | ||||||
Totals | ||||||||
United States | 128,398 | 122,973 | ||||||
Europe (1) | 56,852 | 59,277 | ||||||
Rest of world | 65,551 | 68,148 | ||||||
Total (2) | $ | 250,801 | $ | 250,398 |
(1) | Europe sales include those countries in which we have a direct sales presence, whereas European countries in which we sell through distributors are included in Rest of world. |
(2) | No single customer represented over 10% of our consolidated net sales. No country’s net sales exceeded 10% of our consolidated sales except for the U.S. |
Three Months Ended March 31, | ||||||||
Operating Income from Continuing Operations | 2019 | 2018 | ||||||
Cardiovascular | $ | 989 | $ | 10,258 | ||||
Neuromodulation | 21,631 | 38,734 | ||||||
Other | (28,299 | ) | (22,820 | ) | ||||
Total reportable segment (loss) income from continuing operations | (5,679 | ) | 26,172 | |||||
Merger and integration expenses | 3,251 | 2,960 | ||||||
Restructuring expenses | 2,533 | 1,881 | ||||||
Amortization of intangibles | 9,316 | 8,801 | ||||||
Operating (loss) income from continuing operations | (20,779 | ) | 12,530 | |||||
Interest income | 249 | 447 | ||||||
Interest expense | (1,662 | ) | (2,111 | ) | ||||
Gain on acquisition | — | 11,484 | ||||||
Foreign exchange and other gains (losses) | 729 | (273 | ) | |||||
(Loss) income from continuing operations before tax | $ | (21,463 | ) | $ | 22,077 |
Assets | March 31, 2019 | December 31, 2018 | ||||||
Cardiovascular | $ | 1,561,813 | $ | 1,532,825 | ||||
Neuromodulation | 733,307 | 731,840 | ||||||
Other | 304,424 | 285,036 | ||||||
Total assets | $ | 2,599,544 | $ | 2,549,701 |
Three Months Ended March 31, | ||||||||
Capital expenditures | 2019 | 2018 | ||||||
Cardiovascular | $ | 3,551 | $ | 3,131 | ||||
Neuromodulation | 403 | 347 | ||||||
Other | 929 | 1,443 | ||||||
Discontinued operations | — | 925 | ||||||
Total | $ | 4,883 | $ | 5,846 |
Neuromodulation | Cardiovascular | Other | Total | |||||||||||||
December 31, 2018 | $ | 398,539 | $ | 515,859 | $ | 42,417 | $ | 956,815 | ||||||||
Measurement period adjustments | — | (3,326 | ) | — | (3,326 | ) | ||||||||||
Foreign currency adjustments | 216 | (1,588 | ) | — | (1,372 | ) | ||||||||||
March 31, 2019 | $ | 398,755 | $ | 510,945 | $ | 42,417 | $ | 952,117 |
PP&E | March 31, 2019 | December 31, 2018 | ||||||
United States | $ | 67,611 | $ | 68,862 | ||||
Europe | 108,391 | 112,376 | ||||||
Rest of world | 9,945 | 10,162 | ||||||
Total | $ | 185,947 | $ | 191,400 |
March 31, 2019 | December 31, 2018 | |||||||
Raw materials | $ | 41,662 | $ | 40,387 | ||||
Work-in-process | 21,934 | 15,999 | ||||||
Finished goods | 97,671 | 97,149 | ||||||
$ | 161,267 | $ | 153,535 |
March 31, 2019 | December 31, 2018 | |||||||
Contingent consideration (1) | $ | 42,302 | $ | 18,530 | ||||
Legal and administrative costs | 23,386 | 9,189 | ||||||
CRM purchase price adjustment payable to MicroPort Scientific Corporation | 14,891 | 14,891 | ||||||
Operating lease liabilities (2) | 10,779 | — | ||||||
Product remediation (3) | 11,521 | 13,945 | ||||||
Other amounts payable to MicroPort Scientific Corporation | 5,105 | 9,319 | ||||||
Restructuring related liabilities (4) | 4,396 | 9,393 | ||||||
Provisions for agents, returns and other | 4,549 | 4,934 | ||||||
Derivative contract liabilities (5) | 1,759 | 5,063 | ||||||
Other accrued expenses | 31,848 | 39,021 | ||||||
$ | 150,536 | $ | 124,285 |
(1) | Refer to “Note 7. Fair Value Measurements” |
(2) | Refer to “Note 10. Leases” |
(3) | Refer to “Note 5. Product Remediation Liability” |
(4) | Refer to “Note 4. Restructuring” |
(5) | Refer to “Note 9. Derivatives and Risk Management” |
Issue Date & Standard | Description | Date of Adoption | Effect on Financial Statements or Other Significant Matters | |||
February 2016 ASU No. 2016-02, Leases (Topic 842) and subsequent amendments | The standard requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use (“ROU”) assets and to provide enhanced disclosures. Furthermore, from a lessor perspective, certain of our agreements that allow the customer to use, rather than purchase, our medical devices met the criteria of being a lease in accordance with the new standard. | January 1, 2019 | Adoption of the new standard resulted in the recognition of ROU assets and lease liabilities of approximately $60 million as of January 1, 2019. Refer to “Note 10. Leases.” | |||
June 2018 ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting | This update simplifies the accounting for non-employee share-based payment transactions. | January 1, 2019 | There was no material impact to our condensed consolidated financial statements as a result of adopting this ASU. |
Issue Date & Standard | Description | Projected Date of Adoption | Effect on Financial Statements or Other Significant Matters | |||
June 2016 ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326) | The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The modified-retrospective approach is generally applicable through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Early adoption is permitted. | January 1, 2020 | We are currently evaluating the effect this standard will have on our condensed consolidated financial statements and related disclosures. | |||
January 2017 ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment | This update removes step 2 of the goodwill impairment test that compares the implied fair value of goodwill with its carrying amount. Instead, an impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge will be recorded by the amount a reporting unit’s carrying amount exceeds its fair value. Early adoption is permitted. | January 1, 2020 | We are currently evaluating the effect this standard will have on our condensed consolidated financial statements and related disclosures. | |||
August 2018 ASU No. 2018-13, Fair Value Measurement (Topic 820): Changes to the Disclosure Requirements for Fair Value Measurement | This update removes, modifies and adds certain disclosure requirements related to fair value measurements. Early adoption is permitted. | January 1, 2020 | We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statement disclosures. | |||
August 2018 ASU No. 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General (Subtopic 715-20): Changes to the Disclosure Requirements for Defined Benefit Plans | This update adds and removes certain disclosure requirements related to defined benefit plans. This ASU is to be implemented on a retrospective basis for all periods presented with early adoption permitted. | January 1, 2021 | We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statement disclosures. | |||
August 2018 ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract | This update clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This ASU is to be applied either retrospectively or prospectively with early adoption permitted. | January 1, 2020 | We do not expect the adoption of this update to have a material effect on our condensed consolidated financial statements. |
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Net sales | $ | 250,801 | $ | 250,398 | ||||
Costs and expenses: | ||||||||
Cost of sales - exclusive of amortization | 84,254 | 84,598 | ||||||
Product remediation | 2,947 | 3,715 | ||||||
Selling, general and administrative | 125,704 | 104,161 | ||||||
Research and development | 43,575 | 31,752 | ||||||
Merger and integration expenses | 3,251 | 2,960 | ||||||
Restructuring expenses | 2,533 | 1,881 | ||||||
Amortization of intangibles | 9,316 | 8,801 | ||||||
Operating (loss) income from continuing operations | (20,779 | ) | 12,530 | |||||
Interest income | 249 | 447 | ||||||
Interest expense | (1,662 | ) | (2,111 | ) | ||||
Gain on acquisition | — | 11,484 | ||||||
Foreign exchange and other gains (losses) | 729 | (273 | ) | |||||
(Loss) income from continuing operations before tax | (21,463 | ) | 22,077 | |||||
Income tax (benefit) expense | (6,614 | ) | 3,893 | |||||
Losses from equity method investments | — | (362 | ) | |||||
Net (loss) income from continuing operations | (14,849 | ) | 17,822 | |||||
Net loss from discontinued operations, net of tax | — | (4,549 | ) | |||||
Net (loss) income | $ | (14,849 | ) | $ | 13,273 |
Three Months Ended March 31, | |||||||||||
2019 | 2018 | % Increase (Decrease) | |||||||||
Cardiopulmonary | |||||||||||
United States | $ | 39,123 | $ | 38,445 | 1.8 | % | |||||
Europe | 35,561 | 36,870 | (3.6 | )% | |||||||
Rest of world | 46,886 | 49,815 | (5.9 | )% | |||||||
121,570 | 125,130 | (2.8 | )% | ||||||||
Heart Valves | |||||||||||
United States | 4,356 | 6,536 | (33.4 | )% | |||||||
Europe | 10,513 | 12,116 | (13.2 | )% | |||||||
Rest of world | 10,804 | 12,390 | (12.8 | )% | |||||||
25,673 | 31,042 | (17.3 | )% | ||||||||
Advanced Circulatory Support | |||||||||||
United States | 8,033 | — | — | ||||||||
Europe | 119 | — | — | ||||||||
Rest of world | 96 | — | — | ||||||||
8,248 | — | — | |||||||||
Cardiovascular | |||||||||||
United States | 51,512 | 44,981 | 14.5 | % | |||||||
Europe | 46,193 | 48,986 | (5.7 | )% | |||||||
Rest of world | 57,786 | 62,205 | (7.1 | )% | |||||||
155,491 | 156,172 | (0.4 | )% | ||||||||
Neuromodulation | |||||||||||
United States | 76,886 | 77,992 | (1.4 | )% | |||||||
Europe | 10,659 | 10,291 | 3.6 | % | |||||||
Rest of world | 7,104 | 5,561 | 27.7 | % | |||||||
94,649 | 93,844 | 0.9 | % | ||||||||
Other | 661 | 382 | 73.0 | % | |||||||
Totals | |||||||||||
United States | 128,398 | 122,973 | 4.4 | % | |||||||
Europe (1) | 56,852 | 59,277 | (4.1 | )% | |||||||
Rest of world | 65,551 | 68,148 | (3.8 | )% | |||||||
Total | $ | 250,801 | $ | 250,398 | 0.2 | % |
(1) | Europe sales include those countries in which we have a direct sales presence, whereas European countries in which we sell through distributors are included in “Rest of world.” |
Three Months Ended March 31, | |||||||||||
2019 | 2018 | % Change | |||||||||
Cardiovascular | $ | 989 | $ | 10,258 | (90.4 | )% | |||||
Neuromodulation | 21,631 | 38,734 | (44.2 | )% | |||||||
Other | (28,299 | ) | (22,820 | ) | 24.0 | % | |||||
Total reportable segment income from continuing operations (1) | $ | (5,679 | ) | $ | 26,172 | (121.7 | )% |
(1) | For a reconciliation of segment operating income to consolidated operating income refer to “Note 16. Geographic and Segment Information” in the condensed consolidated financial statements in this Quarterly Report on Form 10-Q. |
Three Months Ended March 31, | |||||||||
2019 | 2018 | Change | |||||||
Cost of sales - exclusive of amortization | 33.6 | % | 33.8 | % | (0.2 | )% | |||
Product remediation | 1.2 | % | 1.5 | % | (0.3 | )% | |||
Selling, general and administrative | 50.1 | % | 41.6 | % | 8.5 | % | |||
Research and development | 17.4 | % | 12.7 | % | 4.7 | % | |||
Merger and integration expenses | 1.3 | % | 1.2 | % | 0.1 | % | |||
Restructuring expenses | 1.0 | % | 0.8 | % | 0.2 | % | |||
Amortization of intangibles | 3.7 | % | 3.5 | % | 0.2 | % |
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Operating activities | $ | 1,974 | $ | 20,393 | ||||
Investing activities | (5,641 | ) | (83,352 | ) | ||||
Financing activities | 7,589 | 32,047 | ||||||
Effect of exchange rate changes on cash and cash equivalents | (350 | ) | 2,261 | |||||
Net increase (decrease) | $ | 3,572 | $ | (28,651 | ) |
Exhibit Number | Document Description |
Stock and Asset Purchase Agreement, dated as of March 8, 2018, by and among the Company, MicroPort Cardiac Rhythm B.V. and MicroPort Scientific Corporation (excluding schedules and exhibits, which the Company agrees to furnish supplementally to the Securities and Exchange Commission upon request), incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K, filed on March 8, 2018 | |
Amended Articles of Association, incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, filed on June 15, 2018 | |
2019 LivaNova Short-Term Incentive Plan approved February 20, 2019, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K/A, filed on March 6, 2019 | |
Commitment Letter dated February 25, 2019, by and among LivaNova PLC and the lenders party thereto | |
US$350 million multicurrency term facilities agreement dated March 26, 2019, by and among LivaNova PLC, the lenders, arrangers and bookrunners, documentation agent and co-ordinator parties thereto and Barclays Bank PLC as agent. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed March 29, 2019 | |
Description of 2019 Long Term Incentive Plan approved March 29, 2019, incorporated by reference to Exhibit 10.1 if the Company’s Current Report on Form 8-K, filed on April 1, 2019 | |
Form of the Company’s 2019 Long Term Incentive Plan RSU Award Agreement, incorporated by reference to Exhibit 10.2 if the Company’s Current Report on Form 8-K, filed on April 1, 2019 | |
Form of the Company’s 2019 Long Term Incentive Plan SAR Award Agreement, incorporated by reference to Exhibit 10.3 if the Company’s Current Report on Form 8-K, filed on April 1, 2019 | |
Form of the Company’s 2019 Long Term Incentive Plan PSU Award Agreement (rTSR condition), incorporated by reference to Exhibit 10.4 if the Company’s Current Report on Form 8-K, filed on April 1, 2019 | |
Form of the Company’s 2019 Long Term Incentive Plan PSU Award Agreement (FCF condition), incorporated by reference to Exhibit 10.5 of the Company’s Current Report on Form 8-K, filed on April 1, 2019 | |
Service Agreement, dated February 28, 2017, between Alistair Simpson and LivaNova PLC | |
Certification of the Chief Executive Officer of LivaNova PLC pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
Certification of the Chief Financial Officer of LivaNova PLC pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
Certification of the Chief Executive Officer and Chief Financial Officer of LivaNova PLC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
101* | Interactive Data Files Pursuant to Rule 405 of Regulation S-T: (i) the Condensed Consolidated Statements of Income (Loss) for the three months ended March 31, 2019 and March 31, 2018, (ii) the Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2019 and March 31, 2018, (iii) the Condensed Consolidated Balance Sheet as of March 31, 2019 and December 31, 2018, (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and March 31, 2018, and (vi) the Notes to the Condensed Consolidated Financial Statements. |
LIVANOVA PLC | ||
By: | /s/ DAMIEN MCDONALD | |
Damien McDonald | ||
Chief Executive Officer | ||
(Principal Executive Officer) |
LIVANOVA PLC | ||
By: | /s/ THAD HUSTON | |
Thad Huston | ||
Chief Financial Officer | ||
(Principal Financial Officer) |
To: | LivaNova PLC (the "Company") |
1. | Appointment |
1.1 | The Company appoints: |
(a) | the Mandated Lead Arrangers as exclusive arrangers of the Facility; |
(b) | the Underwriters as exclusive underwriters of the Facility; |
(c) | the Bookrunners as exclusive bookrunners; |
(d) | Bank of America Merrill Lynch International DAC as documentation agent and coordinator in connection with the Facility (the "Documentation Agent and Coordinator"); and |
(e) | Barclays Bank PLC as facility agent in connection with the Facility. |
1.2 | Until this mandate terminates in accordance with paragraph 12 (Termination): |
(a) | no other person shall be appointed as mandated lead arranger, underwriter, bookrunner, documentation agent and coordinator or facility agent; |
(b) | no other titles shall be awarded; and |
(c) | except as provided in the Mandate Documents, no other compensation shall be paid to any person, |
1.3 | Any of the Mandated Lead Arrangers, Bookrunners and Underwriters may delegate by written notice to the Company any or all of its rights and obligations under this letter to any of its subsidiaries or affiliates (each a "Delegate") and may designate any Delegate as responsible for the performance of any of its appointed functions under this letter. Following designation, a Delegate may rely on this letter. |
2. | Conditions |
2.1 | This offer to arrange and underwrite the Facility is made on the terms of the Mandate Documents and is subject to satisfaction of the following conditions: |
(a) | compliance by the Company with all the terms of each Mandate Document; |
(b) | each of the representations and warranties made by the Company or any other member of the Group in connection with the transaction contemplated in the Mandate Documents (including, but not limited to, those set out in paragraph 6 (Information)) being correct; |
(c) | the preparation, execution and delivery of the Facility Documents by no later than the date falling 60 days after the date of this letter or any later date agreed between the Company and each of the Mandated Lead Arrangers and Underwriters; and |
(d) | completion by each of the Mandated Lead Arrangers and Underwriters of client identification procedures (including, if necessary, identification of directors and major shareholders of the Company) in compliance with applicable money laundering rules. |
3. | Underwriting Proportions |
3.1 | The underwriting proportions of each of the Underwriters in respect of the Facility are as follows: |
Underwriter | Underwriting Proportion (%) | Amount (USD) |
Bank of America Merrill Lynch International DAC | 25 | 87,500,000 |
Barclays Bank PLC | 25 | 87,500,000 |
BNP Paribas, London Branch | 25 | 87,500,000 |
Intesa Sanpaolo S.p.A | 25 | 87,500,000 |
Total | 100 | 350,000,000 |
3.2 | The obligations of the Mandated Lead Arrangers, Bookrunners and the Underwriters under the Mandate Documents are several. No Mandated Lead Arranger is responsible for the obligations of any other Mandated Lead Arranger. No Bookrunner is responsible for the obligations of any other Bookrunner. No Underwriter is responsible for the obligations of any other Underwriter. |
4. | Fees, Costs and Expenses |
4.1 | All fees shall be paid in accordance with the Fee Letter(s) or as set out in the Term Sheet. |
4.2 | The Company shall promptly on demand pay the Agent, the Mandated Lead Arrangers, the Bookrunners and the Underwriters the amount of all costs and expenses (including legal fees) reasonably incurred by any of them in connection with the negotiation, preparation, printing and execution of the Facility Documents and the Mandate Documents whether or not the Facility Documents are signed.The Company acknowledges that each or any of the Mandated Lead Arrangers may receive a benefit, including without limitation, a discount, credit or other accommodation, from any relevant legal counsel based on the legal fees such legal counsel may receive on account of their relationship with the Mandated Lead Arrangers including, without limitation, fees paid pursuant to the Mandate Documents. |
5. | Payments |
(a) | shall be paid in the currency of invoice and in immediately available, freely transferable cleared funds to such account(s) with such bank(s) as the Mandated Lead Arrangers, the Agent, the Bookrunners or the Underwriters (as applicable) notify to the Company; |
(b) | shall be paid without any deduction or withholding for or on account of tax (a "Tax Deduction") unless a Tax Deduction is required by law. If a Tax Deduction is required by law to be made, the amount of the payment due shall be increased to an amount which (after making any Tax Deduction) leaves an amount equal to the payment which would have been due if no Tax Deduction had been required; and |
(c) | are exclusive of any value added tax or similar charge ("VAT"). If VAT is chargeable, the Company shall also and at the same time pay to the recipient of the relevant payment an amount equal to the amount of the VAT. |
6. | Information |
6.1 | The Company represents and warrants that: |
(a) | any factual information provided to the Mandated Lead Arrangers or the Bookrunners by or on behalf of it or any other member of the Group (the "Information") is true and accurate in all material respects as at the date it is provided or as at the date (if any) at which it is stated; |
(b) | nothing has occurred or been omitted and no information has been given or withheld that results in the Information being untrue or misleading in any material respect; and |
(c) | any financial projections contained in the Information have been prepared in good faith on the basis of recent historical information and on the basis of reasonable assumptions. |
6.2 | The representations and warranties set out in paragraph 6.1 are deemed to be made by the Company daily by reference to the facts and circumstances then existing commencing on the date of this letter and continuing until the date the Facility Documents are signed. |
6.3 | The Company shall immediately notify the Mandated Lead Arrangers and the Bookrunners in writing if any representation and warranty set out in paragraph 6.1 is incorrect or misleading and agrees to supplement the Information promptly from time to time to ensure that each such representation and warranty is correct when made. |
6.4 | The Company acknowledges that the Mandated Lead Arrangers, the Bookrunners and the Underwriters will be relying on the Information without carrying out any independent verification. |
7. | Indemnity |
(a) | Whether or not the Facility Documents are signed, the Company shall within three Business Days of demand indemnify each Indemnified Person against any cost, expense, loss or liability (including without limitation legal fees) incurred by or awarded against that Indemnified Person in each case arising out of or in connection with any action, claim, investigation or proceeding commenced or |
(i) | the use of the proceeds of the Facility; |
(ii) | any Mandate Document or any Facility Document; and/or |
(iii) | the arranging or underwriting of the Facility. |
(b) | The Company will not be liable under paragraph (a) above for any cost, expense, loss or liability (including without limitation legal fees) incurred by or awarded against an Indemnified Person if that cost, expense, loss or liability results directly from any breach by that Indemnified Person of any Mandate Document or any Facility Document which is in each case finally judicially determined to have resulted directly from the gross negligence or wilful misconduct of that Indemnified Person. |
(c) | For the purposes of this paragraph 7: |
7.2 | No Mandated Lead Arranger, Bookrunner or Underwriter shall have any duty or obligation, whether as fiduciary for any Indemnified Person or otherwise, to recover any payment made or required to be made under paragraph 7.1. |
(a) | The Company agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company or any of its Affiliates for or in connection with anything referred to in paragraph 7.1 above except, following the Company's agreement to the Mandate Documents, for any such cost, expense, loss or liability incurred by the Company that results directly from any breach by that Indemnified Person of any Mandate Document or any Facility Document which is in each case finally judicially determined to have resulted directly from the gross negligence or wilful misconduct of that Indemnified Person. |
(b) | Notwithstanding paragraph (a) above, no Indemnified Person shall be responsible or have any liability to the Company or any of its Affiliates or anyone else for consequential losses or damages. |
(c) | The Company represents to the Mandated Lead Arrangers, the Bookrunners and Underwriters that: |
(i) | it is acting for its own account and it has made its own independent decisions to enter into the transaction contemplated in the Mandate Documents (the "Transaction") and as to whether the Transaction is |
(ii) | it is not relying on any communication (written or oral) from any or all of the Mandated Lead Arrangers, the Bookrunners or Underwriters as investment advice or as a recommendation to enter into the Transaction, it being understood that information and explanations related to the terms and conditions of the Transaction shall not be considered investment advice or a recommendation to enter into the Transaction. No communication (written or oral) received from any or all of the Mandated Lead Arrangers, Bookrunners or Underwriters shall be deemed to be an assurance or guarantee as to the expected results of the Transaction; |
(iii) | it is capable of assessing the merits of and understanding (on its own behalf or through independent professional advice), and understands and accepts, the terms, conditions and risks of the Transaction. It is also capable of assuming, and assumes, the risks of the Transaction; and |
(iv) | no Mandated Lead Arranger, Bookrunner or Underwriter is acting as a fiduciary for or as an adviser to it in connection with the Transaction. |
7.4 | The Contracts (Rights of Third Parties) Act 1999 shall apply to this paragraph 7 but only for the benefit of the other Indemnified Persons, subject always to the terms of paragraphs 15.2 and 17 (Governing Law and Jurisdiction). |
8. | Confidentiality |
(a) | as required by law or by any applicable governmental or other regulatory authority or by any applicable stock exchange; and |
(b) | to its employees or professional advisers for the purposes of the Facility who have been made aware of and agree to be bound by the obligations under this paragraph or are in any event subject to confidentiality obligations as a matter of law or professional practice. |
9. | Publicity/Announcements |
9.1 | All publicity in connection with the Facility shall be managed by the Mandated Lead Arrangers in consultation with the Company. |
9.2 | No announcements regarding the Facility or any roles as arranger, underwriter, bookrunner, lender or agent shall be made without the prior written consent of the Company and each of the Mandated Lead Arrangers, Bookrunners and Underwriters. |
10. | Conflicts |
10.1 | The Company and each Mandated Lead Arranger, Bookrunner and Underwriter acknowledges that the Mandated Lead Arrangers or their Affiliates, the Bookrunners or their Affiliates and the Underwriters or their Affiliates may provide debt financing, equity capital or other services to other persons with whom the Company or its Affiliates may have conflicting interests in respect of the Facility in this or other transactions. |
10.2 | The Company and each Mandated Lead Arranger, Bookrunner and Underwriter acknowledges that the Mandated Lead Arrangers or their Affiliates, the Bookrunners or their Affiliates and the Underwriters or their Affiliates may act in more than one capacity in relation to this transaction and may have conflicting interests in respect of such different capacities. |
10.3 | The Mandated Lead Arrangers, Bookrunners and Underwriters shall not use confidential information obtained from the Company or its Affiliates for the purposes of the Facility in connection with providing services to other persons or furnish such information to such other persons. |
10.4 | The Company acknowledges that the Mandated Lead Arrangers, Bookrunners and Underwriters have no obligation to use any information obtained from another source for the purposes of the Facility or to furnish such information to the Company or its Affiliates. |
11. | Assignments |
11.1 | The Company shall not assign any of its rights or transfer any of its rights or obligations under the Mandate Documents without the prior written consent of each of the Mandated Lead Arrangers, the Bookrunners and Underwriters. |
12. | Termination |
12.1 | If the Company does not accept the offer made by each of the Mandated Lead Arrangers, Bookrunners and Underwriters in this letter by countersigning this letter and the Fee Letter setting out the Upfront Fee referred to in the Term Sheet before close of business in London on the date falling five Business Days after the date of this letter, such offer shall terminate on that date. |
12.2 | Any Mandated Lead Arranger, Bookrunner or Underwriter may terminate its obligations under this letter with immediate effect by notifying the Company and the other Mandated Lead Arranger(s), Bookrunner(s) and Underwriter(s) if in its opinion, any of the conditions set out in paragraph 2 (Conditions) is not satisfied; |
13. | Survival |
13.1 | Except for paragraphs 2 (Conditions), 3 (Underwriting Proportions) and 12 (Termination) the terms of this letter shall survive and continue after the Facility Documents are signed. |
13.2 | Without prejudice to paragraph 13.1, paragraphs 4 (Fees, Costs and Expenses), 5 (Payments), 7 (Indemnity), 8 (Confidentiality), 9 (Publicity/Announcements), 10 (Conflicts) and 12 (Termination) to 17 (Governing Law and Jurisdiction) inclusive shall survive and continue after any termination of the obligations of any Mandated Lead Arranger, Bookrunner or Underwriter under the Mandate Documents. |
14. | Entire Agreement |
14.1 | The Mandate Documents set out the entire agreement between the Company, the Mandated Lead Arrangers, the Bookrunners and the Underwriters as to arranging and underwriting the Facility and supersede any prior oral and/or written understandings or arrangements relating to the Facility. |
14.2 | Any provision of a Mandate Document may only be amended or waived in writing signed by the Company and each of the Mandated Lead Arrangers, Bookrunners and Underwriters. |
15. | Third Party Rights |
15.1 | Unless expressly provided to the contrary in this letter, a person who is not a party to this letter has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce or to enjoy the benefit of any of its terms. |
15.2 | Notwithstanding any term of this letter, the consent of any person who is not a party to this letter is not required to rescind or vary this letter at any time. |
16. | Counterparts |
17. | Governing Law and Jurisdiction |
17.1 | This letter (including the agreement constituted by your acknowledgement of its terms) (the "Letter") and any non-contractual obligations arising out of or in connection with it (including any non-contractual obligations arising out of the negotiation of the transaction contemplated by this Letter) are governed by English law. |
17.2 | The courts of England have non-exclusive jurisdiction to settle any dispute arising out of or in connection with this Letter (including a dispute relating to any non-contractual obligation arising out of or in connection with either this Letter or the negotiation of the transaction contemplated by this Letter). |
/s/ Stefano Boniello For and on behalf of Intesa Sanpaolo S.p.A as Mandated Lead Arranger Name: Stefano Boniello Title: Global Relationship manager | /s/ Guido Austoni For and on behalf of Intesa Sanpaolo S.p.A as Mandated Lead Arranger Name: Guido Austoni Title: Global Head of Basic Materials & Healthcare |
/s/ Stefano Boniello For and on behalf of Intesa Sanpaolo S.p.A as Bookrunner Name: Stefano Boniello Title: Global Relationship manager | /s/ Guido Austoni For and on behalf of Intesa Sanpaolo S.p.A as Bookrunner Name: Guido Austoni Title: Global Head of Basic Materials & Healthcare |
/s/ Stefano Boniello For and on behalf of Intesa Sanpaolo S.p.A as Underwriter Name: Stefano Boniello Title: Global Relationship manager | /s/ Guido Austoni For and on behalf of Intesa Sanpaolo S.p.A as Underwriter Name: Guido Austoni Title: Global Head of Basic Materials & Healthcare |
The provision of the Facility is subject to the terms and conditions of the Commitment Letter and satisfactory documentation. |
Company: | LivaNova PLC |
Borrower: | The Company |
Mandated Lead Arrangers and Bookrunners: | Bank of America Merrill Lynch International DAC, Barclays Bank PLC, BNP Paribas, London Branch and Intesa Sanpaolo S.p.A. |
Lenders: | As selected by the Mandated Lead Arrangers in consultation with the Company. |
Documentation Agent and Coordinator: | Bank of America Merrill Lynch International DAC |
Agent: | Barclays Bank PLC. |
Group: | The Company and its Subsidiaries for the time being. |
Facility: | Multicurrency term loan facility. |
Amount: | USD350,000,000 to be made available in two tranches (each a “Tranche”) (i) USD233,333,333 (the “USD Tranche”) and (ii) EUR equivalent of USD116,666,667 to be determined prior to the date of the Agreement (the “EUR Tranche”); provided that the amounts utilised shall be in a ratio of 2/3 USD Tranche and 1/3 EUR Tranche (calculated using the same exchange rate used in determining the EUR equivalent of USD116,666,667 as referred to above in (ii)). |
Termination Date: | 3 years after the date of the Agreement. |
Purpose: | General corporate purposes (excluding acquisitions, dividends and share buybacks). |
Availability Period: | From the date of the Agreement to the date which is 12 months after the date of the Agreement. |
Minimum Amount of each Loan: | USD 4,000,000 / EUR equivalent of USD 2,000,000 as applicable. |
Maximum Number of Loans: | No more than 5 Loans in respect of the USD Tranche and no more than 5 Loans in respect of the EUR Tranche, being an aggregate of 10 Loans, may be outstanding. |
Repayment: | The Company shall repay the Loans in instalments by repaying on each Repayment Date an amount equal to the percentage of the outstanding principal amount of the Loans under the relevant Tranche as at the last day of the Availability Period set opposite that Repayment Date below: |
Voluntary Prepayment: | Loans may be prepaid after the last day of the Availability Period in whole or in part on five Business Days' (or such shorter period as the Agent may agree) prior notice (but, if in part, by a minimum of USD4,000,000 / EUR equivalent of USD2,000,000 (as applicable)). Any prepayment shall be made with accrued interest on the amount prepaid and, subject to breakage costs, without premium or penalty. |
Any amount prepaid may not be redrawn and shall be applied pro rata against scheduled repayments of Loans outstanding; provided that the Loans prepaid shall be in a ratio 2/3 USD Tranche and 1/3 EUR Tranche. |
Upfront Fee: | 1 per cent of the aggregate principal amount of the Facility as at the date of the Commitment Letter payable pursuant to the Upfront Fee Letter between the Company and the Mandated Lead Arrangers dated on or about the date of the Commitment Letter. |
Documentation Agent and Coordinator Fee: | To be agreed between the Company and the Documentation Agent and Coordinator in a separate Fee Letter. |
Agency Fee: | To be agreed between the Company and the Agent in a separate Fee Letter. |
Commitment Fee: | 35 per cent. of the applicable Margin on the unused and uncancelled amount of relevant Tranche for the Availability Period. Accrued commitment fee is payable quarterly in arrear during the Availability Period, on the last day of the Availability Period and on the cancelled amount of the relevant Tranche at the time a full cancellation is effective. |
Margin: | In relation to the USD Tranche, 1.60 per cent. per annum; and In relation to the EUR Tranche, 1.40 per cent. per annum. |
Interest Periods for Loans: | Three months or any other period agreed between the Company, the Agent and the Lenders (in relation to the relevant Loan). |
Interest on Loans: | The aggregate of the applicable: |
(a) Margin; and | |
(b) interest rate benchmark. | |
Interest rate benchmarks: | In relation to any Loan in EUR, EURIBOR and, in relation to any Loan in USD, LIBOR set, in each case, by reference to Thomson Reuters (and, if necessary, the use of linear interpolation) or, if not available, by reference to specified fallbacks and if the rate is less than zero, it shall be deemed to be zero. |
Any interest rate benchmark which is not available by reference to Thomson Reuters may be replaced with the consent of the Majority Lenders and the Company. Interest rate benchmarks shall be set by reference to Thomson Reuters without taking account of any correction, recalculation or republication of the originally published rate by the administrator. | |
Payment of Interest on Loans: | Interest is payable on the last day of each Interest Period (and, in the case of Interest Periods of longer than six months, on the dates falling at six-monthly intervals after the first day of the Interest Period). |
Documentation: | The Facility will be made available under a facility agreement based on the current recommended form of multicurrency syndicated term facility agreement (investment grade) of the LMA, this Term Sheet and otherwise in form and substance satisfactory to the Mandated Lead Arrangers acting reasonably and having regard to the USD 170,000,000 bridge facility agreement dated 14 February 2018 and entered into between the Company and Bank of America Merrill Lynch International Limited to resolve any disputes. |
Prepayment and Cancellation: | (a) Illegality A Lender may cancel its Commitment and require prepayment of its share of the Loans. |
(b) Change of Control If a Change of Control occurs: | |
(1) a Lender shall not be obliged to fund a Loan; and | |
(2) a Lender may by not less than 30 days' notice cancel its Commitment and require repayment of all its share of the Loans. “Change of Control” means: (1) any person or group of persons acting in concert gain direct or indirect control of the Company; or (2) the Company ceases to be the beneficial owner directly or indirectly through wholly owned subsidiaries, of more than 50 per cent of the issued share capital of the Italian Subsidiary “acting in concert” means acting together pursuant to an agreement or understanding (whether formal or informal). “control” means the power to direct the management and policies of an entity, whether through the ownership of more than 50 per cent of entire voting capital, by contract or otherwise | |
(c) Increased Costs, Tax Gross Up and Tax Indemnity The Company may cancel the Commitment of and prepay any Lender that makes a claim under these provisions. | |
(d) Voluntary Cancellation The Company may, on not less than five Business Days' (or such shorter period as the Agent may agree) prior notice, cancel the whole or any part (being a minimum of USD4,000,000 / EUR equivalent of USD2,000,000) of the Available Facility. The Available Facility shall, if cancelled in part, be cancelled in a ratio of 2/3 USD Tranche and 1/3 EUR Tranche. | |
Representations: | The Company will make the representations set out in Schedule 1 (Representations) to this Term Sheet (i) on the date of the Agreement (except for representations and warranties in paragraph 11(a) and (b) of Schedule 1 (Representations) to this Term Sheet which shall be made on the date such information or projections are delivered) and (ii) in the case of paragraphs 1 to 6, 10(a), 12(d), 19, 20 and 24 of Schedule 1 (Representations) to this Term Sheet, on the date of each Utilisation Request and the first day of each Interest Period |
Information Undertakings: | The Company shall supply each of the following: |
(a) as soon as they become available, but in any event within 180 days of the end of its financial years its audited consolidated financial statements for that financial year | |
(b) as soon as they become available, but in any event within 90 days of the end of each of its financial half years ending 30 June its consolidated financial statements for that financial half year | |
(c) with each set of consolidated financial statements, a compliance certificate setting out (in reasonable detail) computations as to compliance with the financial covenants as at the date at which those financial statements were drawn up | |
(d) all material documents dispatched by the Company to its shareholders (or any class of them) or its creditors (or any class of them) at the same time as they are dispatched | |
(e) promptly upon becoming aware of them, the details of any material litigation, arbitration or administrative proceedings which are current, threatened or pending against any member of the Group, and which are likely to be adversely determined and if adversely determined, would have a Material Adverse Effect | |
(f) promptly, such further information regarding the financial condition, assets, business and operations of any member of the Group as any Finance Party may reasonably request | |
(g) promptly, notify the Agent upon becoming aware of the occurrence of any Default (h) promptly upon request by the Agent, certificate signed by two of its directors or senior officers that no Default is continuing or if a Default is continuing specifying the Default and the steps (if any) being taken to remedy it | |
On the introduction of or any change in law, a change in the status of the Company or a proposed assignment or transfer by a Lender to a party that is not an existing Lender, which obliges a Lender to comply with "know your customer" or similar identification procedures in circumstances where the necessary information is not already available to it, the Company shall promptly upon the request of the Agent or any Lender supply such documentation and other evidence as is reasonably requested by the Agent (for itself and on behalf of any Lender) or any Lender (or prospective new Lender) in order for the Agent or such Lender (or prospective new Lender) to carry out and be satisfied with the results of all necessary "know your customer" or other checks in relation to the transactions contemplated in the Finance Documents. | |
Financial Covenants: | The financial undertakings set out in Schedule 2 (Financial Undertakings) to this Term Sheet will be included in the Agreement |
General Undertakings: | The undertakings set out in Schedule 3 (General Undertakings) to this Term Sheet will be included in the Agreement in respect of the Company and, where applicable, in relation to the Group |
Events of Default: | Each of the events or circumstances set out in Schedule 4 (Events of Default) to this Term Sheet will be included in the Agreement in respect of the Company and, if appropriate, any member of the Group |
Majority Lenders: | 66⅔% of Total Commitments. |
Assignments and Transfers by Lenders: | Subject to the following paragraph, a Lender may assign any of its rights or transfer by novation any of its rights and obligations to another bank or financial institution or to a trust, fund or other entity which is regularly engaged in or established for the purpose of making, purchasing or investing in loans, securities or other financial assets. |
The consent of the Company will be required (not to be unreasonably withheld or delayed) unless the transfer or assignment is to another Lender or an Affiliate or a Related Fund of a Lender or is made at a time when an Event of Default is continuing, provided that no transfer or assignment shall be made to any person whose business is similar or related to the business carried on by the Group as a whole (or to an Affiliate of any such person or any such person acting on behalf of or on the instructions of any such person) or to a Distressed Fund without the prior written consent of the Borrower (at its sole discretion). The Company will be deemed to have given its consent if no express refusal is received within 5 Business Days. | |
Conditions Precedent: | These will include the documents and other evidence set out in Schedule 5 (Conditions Precedent) to this Term Sheet in form and substance satisfactory to the Agent |
Miscellaneous Provisions: | The Agreement will contain provisions relating to, among other things, default interest, market disruption, breakage costs, tax gross up and indemnities including FATCA, increased costs (including Basel III and CRDIV), set-off, replacement of screen rate, bail-in and administration. |
Costs and Expenses: | Subject to any agreed caps, all costs and expenses (including legal fees) reasonably incurred by the Agent and the Mandated Lead Arrangers in connection with the preparation, negotiation, printing, execution and syndication of the Agreement and any other document referred to in it shall be paid by the Company promptly on demand whether or not the Agreement is signed. |
Governing Law: | English. |
Jurisdiction: | Courts of England. |
Definitions: | Terms defined in the current recommended form of mulitcurrency syndicated term facility agreement (investment grade) of the LMA have the same meaning in this Term Sheet unless given a different meaning in this Term Sheet (including in Schedule 6 (Certain Definitions) to this Term Sheet). |
1. | Status |
(a) | It is a corporation, duly incorporated and validly existing under the law of its jurisdiction of incorporation. |
(b) | It and each of its Subsidiaries has the power to own its assets and carry on its business as it is being conducted. |
2. | Binding obligations |
3. | Non‑conflict with other obligations |
(a) | any law or regulation applicable to it; |
(b) | its or any of its Subsidiaries' constitutional documents; or |
(c) | any agreement or instrument binding upon it or any of its Subsidiaries or any of its or any of its Subsidiaries' assets. |
4. | Power and authority |
5. | Validity and admissibility in evidence |
(a) | to enable it lawfully to enter into, exercise its rights and comply with its obligations in the Finance Documents; and |
(b) | to make the Finance Documents admissible in evidence in its jurisdiction of incorporation, |
6. | Governing law and enforcement |
(a) | the choice of English law as the governing law of the Finance Documents will be recognised and enforced in its jurisdiction of incorporation; and |
(b) | any judgment obtained in England in relation to a Finance Document will be recognised and enforced in its jurisdiction of incorporation. |
7. | Insolvency |
(a) | corporate action, legal proceeding or other procedure or step described in paragraph 7(a) of Schedule 4 (Events of Default) to this Term Sheet; or |
(b) | creditors' process described in paragraph 8 (Creditor’s process) of Schedule 4 (Events of Default) to this Term Sheet, |
8. | No filing or stamp taxes |
9. | Deduction of Tax |
10. | No default |
(a) | No Event of Default is continuing or might reasonably be expected to result from the making of any Utilisation. |
(b) | No other event or circumstance is outstanding which constitutes a default under any other agreement or instrument which is binding on it or any of its Material Subsidiaries or to which its (or any of its Material Subsidiaries') assets are subject which would have a Material Adverse Effect. |
11. | No misleading information |
(a) | Any material factual information provided by any member of the Group to any Finance Party was true and accurate in all material respects as at the date it was provided or as at the date (if any) at which it is stated. |
(b) | The financial projections provided by the Group to any Finance Party have been prepared on the basis of recent historical information and on the basis of reasonable assumptions. |
(c) | Nothing has occurred since the date that any such information was provided or been omitted from such information provided and no information has been given or withheld that results in the information provided being untrue or misleading in any material respect. |
12. | Financial statements |
(a) | Its Original Financial Statements were prepared in accordance with the Accounting Principles consistently applied (other than any differences arising between IFRS, as used in the preparation of the Original Financial Statements, and the Accounting Principles). |
(b) | Its Original Financial Statements fairly represent its financial condition as at the end of the relevant financial year during the relevant financial year (consolidated in the case of the Borrower). |
(c) | There has been no material adverse change in the business or consolidated financial condition of the Group since the date of its Original Financial Statements. |
(d) | Its most recent financial statements required to be delivered in accordance with the Term Sheet: |
(i) | have been prepared in accordance with the Accounting Principles as applied to the Original Financial Statements (other than any differences arising between IFRS, as used in the preparation of the Original Financial Statements, and the Accounting Principles); and |
(ii) | fairly represent in all material respects its consolidated financial condition as at the end of, and consolidated results of operations for, the period to which they relate. |
13. | No proceedings pending or threatened |
14. | No breach of laws |
(a) | It has not (and none of its Subsidiaries has) breached any law or regulation which breach has or is reasonably likely to have a Material Adverse Effect. |
(b) | No labour disputes are current or, to the best of its knowledge and belief (having made due and careful enquiry), threatened against any member of the Group which have or are reasonably likely to have a Material Adverse Effect. |
15. | Environmental laws |
(a) | Each member of the Group is in compliance with paragraph 3 (Environmental Compliance) of Schedule 3 (General Undertakings) to this Term Sheet and to the best of its knowledge and belief (having made due and careful enquiry) no circumstances have occurred which would prevent such compliance in a manner or to an extent which has or is reasonably likely to have a Material Adverse Effect. |
(b) | No Environmental Claim has been commenced or (to the best of its knowledge and belief (having made due and careful enquiry)) is threatened against any member of the Group where that claim has or is reasonably likely, if determined against that member of the Group, to have a Material Adverse Effect. |
(c) | The cost to the Group of compliance with Environmental Laws (including Environmental Permits) is (to the best of its knowledge and belief, having made due and careful enquiry) adequately provided for. |
16. | Taxation |
(a) | It is not (and none of its Material Subsidiaries is) materially overdue in the filing of any Tax returns and it is not (and none of its Material Subsidiaries is) overdue in the payment of any material amount in respect of Tax unless and only to the extent that: |
(i) | such payment is being contested, postponed or compromised in good faith; |
(ii) | adequate reserves are being maintained for those Taxes and the costs required to contest, postpone or compromise them; and |
(iii) | such payment can be lawfully withheld and failure to pay those Taxes does not have, or to the Borrower's knowledge, would not reasonably be expected to have a Material Adverse Effect. |
(b) | No claims or investigations that are not provided for in its latest financial statements are being made or conducted against it (or any of its Material Subsidiaries) with respect to Taxes such that a liability of the Borrower or any Material Subsidiary of USD 20,000,000 (or its equivalent in any other currency) or more is reasonably likely to arise upon a final determination of that claim or investigation. |
(c) | It is resident for Tax purposes only in England and Wales. |
17. | Security and Financial Indebtedness |
(a) | No Security exists over all or any of the present or future assets of any member of the Group other than as permitted by the Agreement. |
(b) | No member of the Group has any Financial Indebtedness outstanding that is prohibited under paragraph 18 (Financial Indebtedness) of Schedule 3 (General Undertakings) to this Term Sheet. |
18. | Pari passu ranking |
19. | Good title to assets |
20. | Legal and beneficial ownership |
21. | Intellectual Property |
(a) | is the sole legal and beneficial owner of or has licensed to it on normal commercial terms all the Intellectual Property which is material in the context of its business and which is required by it in order to carry on its business as it is being conducted; |
(b) | does not (nor does any of its Subsidiaries), in carrying on its businesses, infringe any Intellectual Property of any third party in any respect; and |
(c) | has taken all formal or procedural actions (including payment of fees) required to maintain any material Intellectual Property owned by it, |
22. | Accounting Reference Date |
23. | No adverse consequences |
(a) | It is not necessary under the laws of its Relevant Jurisdictions: |
(i) | in order to enable any Finance Party to enforce its rights under any Finance Document; or |
(ii) | by reason of the execution of any Finance Document or the performance by it of its obligations under any Finance Document, |
(b) | No Finance Party is or will be deemed to be resident, domiciled or carrying on business in its Relevant Jurisdictions by reason only of the execution, performance and/or enforcement of any Finance Document. |
24. | Centre of main interests and establishments |
25. | Anti‑corruption and anti-money laundering law |
26. | Sanctions |
(a) | To the best of its knowledge and belief (after due and careful enquiry), neither it nor any of its Subsidiaries, nor any directors, officers or employees of it or any of its Subsidiaries: |
(i) | is a Restricted Party or is engaging in or has engaged in any transaction or conduct that could result in it becoming a Restricted Party; |
(ii) | is subject to any claim, proceeding, formal notice or investigation with respect to Sanctions; |
(iii) | is engaging in any transaction that evades or avoids, or has the purpose of evading or avoiding, or breaches or attempts to breach, directly or indirectly, any Sanctions applicable to it; or |
(iv) | is engaging, directly or indirectly, in any trade, business or other activities with or for the benefit of any Restricted Party where such trade, business or activity is in breach of Sanctions. |
(b) | No Utilisation, nor the proceeds from any Utilisation, has been used, directly or (knowingly) indirectly, to lend, contribute, provide or has otherwise been made to fund or finance any business activities or transactions: |
(i) | of or with a Restricted Party; or |
(ii) | in any other manner which would result in any member of the Group, any Finance Party being in breach of any Sanctions or becoming a Restricted Party. |
1. | Financial condition |
(a) | Consolidated Net Financial Indebtedness to Consolidated EBITDA: The Company shall ensure that Consolidated Net Financial Indebtedness as at any Accounting Date shall not be more than 2.50 times the Consolidated EBITDA for the Test Period ending on that Accounting Date. |
(b) | Consolidated EBITDA to Consolidated Total Net Interest Payable: Consolidated EBITDA for the Test Period ending on an Accounting Date shall not be lower than 6.30 times the Consolidated Total Net Interest Payable for that Test Period. |
(c) | Consolidated Net Financial Indebtedness to Consolidated Net Worth: Consolidated Net Financial Indebtedness as at any Accounting Date shall not be more than 0.50 times the Consolidated Net Worth as at that Accounting Date. |
(d) | Consolidated Net Worth: the Consolidated Net Worth shall at no time be lower than USD 725,000,000. |
2. | Financial covenant calculations |
3. | Definitions |
(a) | plus depreciation and amortization expenses for plant, property and equipment; and |
(b) | plus amortization of intangible assets and impairment losses; and |
(c) | plus restructuring, merger and integration expenses; and |
(d) | plus litigation expenses; and |
(e) | plus extraordinary and non-cash items of expense, but only to the extent such items have been deducted in the determination of operating income; |
(f) | minus extraordinary and non-cash items of income, but only to the extent such items are included in the operating income. |
(a) | the aggregate at that time of Financial Indebtedness of the members of the Group from sources external to the Group (including guarantees for an aggregate amount exceeding USD 40,000,000.00 (forty million US dollars) at that time); less |
(b) | the aggregate amount at that time of: (i) cash; (ii) debt securities issued or guaranteed by any member state of the OECD that benefit from an investment grade rating; and (iii) receivables from any derivative transaction entered into in connection with protection against or benefit from fluctuation in any rate or price. |
(a) | interest accrued during such period as an obligation of any member of the Group (whether or not paid or capitalised during or deferred for payment after such period); less |
(b) | any interest received or receivable by any member of the Group (after deducting any applicable withholding tax) in such period. |
1. | Authorisations |
(a) | obtain, comply with and do all that is necessary to maintain in full force and effect; and |
(b) | supply certified copies to the Agent of, |
2. | Compliance with laws |
3. | Environmental compliance |
(a) | comply with all Environmental Law; |
(b) | obtain, maintain and ensure compliance with all requisite Environmental Permits; |
(c) | implement procedures to monitor compliance with and to prevent liability under any Environmental Law, |
4. | Environmental claims |
(a) | any Environmental Claim against any member of the Group which is current, pending or threatened; and |
(b) | any facts or circumstances which are reasonably likely to result in any Environmental Claim being commenced or threatened against any member of the Group, |
5. | Pari passu ranking |
6. | Insurance |
(a) | The Borrower shall (and it shall ensure that each other member of the Group will) maintain insurances on and in relation to its business and assets against those risks and to the extent as is usual for companies carrying on the same or substantially similar business. |
(b) | All insurances must be with reputable independent insurance companies or underwriters. |
7. | Intellectual Property |
(a) | preserve and maintain the subsistence and validity of its material Intellectual Property necessary for the business of the relevant Group member; |
(b) | use reasonable endeavours to prevent any infringement in any material respect of such Intellectual Property; |
(c) | make registrations and pay all registration fees and taxes necessary to maintain such Intellectual Property in full force and effect and record its interest in that Intellectual Property; |
(d) | not use or permit such Intellectual Property to be used in a way or take any step or omit to take any step in respect of that Intellectual Property which may materially and adversely affect the existence or value of such Intellectual Property or imperil the right of any member of the Group to use such property; and |
(e) | not discontinue the use of such Intellectual Property, |
8. | Access |
9. | Preservation of assets |
10. | Taxation |
(a) | The Borrower shall (and it shall ensure that each other member of the Group will) pay and discharge all Taxes of a material amount imposed upon it or its assets within the time period allowed without incurring penalties unless and only to the extent that: |
(i) | such payment is being contested in good faith; |
(ii) | adequate reserves are being maintained for those Taxes and the costs required to contest them which have been disclosed in its latest financial statements required to be delivered to the Agent in accordance with the Term Sheet; and |
(iii) | such payment can be lawfully withheld and failure to pay those Taxes does not have or is not reasonably likely to have a Material Adverse Effect. |
(b) | The Borrower shall not (and it shall ensure that each member of the Group will not) change its residence for Tax purposes. |
11. | Anti‑corruption and anti-money laundering law |
(a) | The Borrower shall not (and it shall ensure that no other member of the Group will) directly or indirectly use the proceeds of the Facilities for any purpose which would breach the Bribery Act 2010, the United States Foreign Corrupt Practices Act of 1977 or other similar legislation in other jurisdictions. |
(b) | The Borrower shall (and it shall ensure that each other member of the Group will): |
(i) | conduct its businesses in compliance with: |
(A) | (other than in respect of matters referred to in paragraph (B) below) applicable anti‑corruption laws and all applicable anti-money laundering and counter-terrorist financing laws and regulations; and |
(B) | all record keeping or reporting requirements required pursuant to any applicable anti-money laundering or counter-terrorist financing laws or regulations in each case in all material respects; and |
(ii) | maintain policies and procedures designed to promote and achieve compliance with such laws. |
12. | Sanctions |
(a) | use, lend, contribute or otherwise make available any part of the proceeds of any Utilisation or other transaction contemplated: |
(i) | for the purpose of financing any trade, business or other activities involving, or for the benefit of, any Restricted Party; or |
(ii) | in any other manner that would result in any person being in breach of any Sanctions or becoming a Restricted Party; |
(b) | knowingly engage in any transaction that evades or avoids or breaches directly or indirectly, any Sanctions applicable to it; or |
(c) | knowingly fund all or part of any payment in connection with a Finance Document out of proceeds derived from business or transactions with a Restricted Party, or from any action which is in breach of any Sanctions. |
13. | Negative pledge |
(a) | The Borrower shall not (and it shall ensure that no other member of the Group will) create or permit to subsist any Security over any of its assets. |
(b) | The Borrower shall not (and it shall ensure that no other member of the Group will): |
(i) | sell, transfer or otherwise dispose of any of its assets on terms whereby they are or may be leased to or re‑acquired by the Borrower or any other member of the Group; |
(ii) | sell, transfer or otherwise dispose of any of its receivables on recourse terms; |
(iii) | enter into any arrangement under which money or the benefit of a bank or other account may be applied, set‑off or made subject to a combination of accounts; or |
(iv) | enter into any other preferential arrangement having a similar effect, |
(v) | in circumstances where the arrangement or transaction is entered into primarily as a method of raising Financial Indebtedness or of financing the acquisition of an asset. |
(c) | Paragraphs 13(a) and 13(b) do not apply to any Permitted Security: |
14. | Loans or credit |
(a) | Except as permitted under paragraph 14(b), the Borrower shall not (and it shall ensure that no other member of the Group will) be a creditor in respect of any Financial Indebtedness. |
(b) | Paragraph 14(a) does not apply to a Permitted Loan. |
15. | Acquisitions |
(a) | Except as permitted under paragraph 15(b), the Borrower shall not (and it shall ensure that no other member of the Group will) acquire a company or any shares or securities or a business or undertaking (or any interest in any of them). |
(b) | Paragraph 15(a) does not apply to an acquisition that is a Permitted Acquisition. |
16. | Merger |
(a) | The Borrower shall not (and it shall ensure that no other member of the Group will) enter into any amalgamation, demerger, merger or corporate reconstruction. |
(b) | Paragraph 16(a) does not apply to any Permitted Transaction. |
17. | No Guarantees or indemnities |
(a) | Except as permitted under paragraph 17(b), the Borrower shall not (and it shall ensure that no other member of the Group will) incur or allow to remain outstanding any guarantee in respect of any obligation of any person. |
(b) | Paragraph 17(a) does not apply to a guarantee which is a Permitted Guarantee. |
18. | Financial Indebtedness |
(a) | The Borrower shall ensure that the Subsidiary Financial Indebtedness does not exceed at any time 35 per cent of Group Financial Indebtedness. |
(b) | For the purposes of this paragraph 18: |
(c) | For the avoidance of doubt and notwithstanding anything to the contrary, intra‑group debt shall not constitute or in any way be included in the definition of Financial Indebtedness or Subsidiary Financial Indebtedness. |
19. | Disposal of assets |
(a) | Except as permitted under paragraph 19(b), the Borrower shall not (and it shall ensure that no other member of the Group will) enter into a single transaction or a series of transactions (whether related or not) and whether voluntary or involuntary to sell, lease, transfer or otherwise dispose of any asset. |
(b) | Paragraph 19(a) does not apply to any sale, lease, transfer or other disposal for fair market value and at arm’s length: |
(i) | made in the ordinary course of trading of the disposing entity; |
(ii) | of assets in exchange of other assets comparable or superior as to type, value and quality; |
(iii) | of obsolete or redundant vehicles, plant and equipment for cash; |
(iv) | of receivables being part of Permitted Receivables Disposals; or |
(v) | of assets not falling within paragraphs 19(b)(i) to 19(b)(iv), provided that over the life of the Facility the aggregate value of the disposed assets and other disposals of assets not falling within paragraphs 19(b)(i) to 19(b)(iv), shall not exceed 10 per cent of the total assets of the Group as reports in the latest audited consolidated financial statements. |
20. | Change of business |
21. | Arm's length basis |
22. | Amendments |
(a) | The Borrower shall not (and it shall ensure that no other member of the Group will) amend, vary, novate, supplement, supersede, waive or terminate any term of any document delivered to the Agent pursuant to Schedule 5 (Conditions Precedent) to this Term Sheet except in writing: |
(i) | in accordance with the Agreement; |
(ii) | prior to or on the first Utilisation Date, with the prior written consent of the Lenders; or |
(iii) | after the first Utilisation Date, in a way which could not be reasonably expected materially and adversely to affect the interests of the Lenders. |
(b) | The Borrower shall promptly supply to the Agent a copy of any document relating to any of the matters referred to in paragraphs 22(a)(i) to 22(a)(iii). |
23. | Accounting practices |
1. | Non‑payment |
(a) | its failure to pay is caused by: |
(i) | administrative or technical error; or |
(ii) | a Disruption Event; and |
(b) | payment is made within five Business Days of its due date. |
2. | Financial covenants |
3. | Other obligations |
(a) | The Borrower does not comply with any provision of the Finance Documents (other than those referred to in paragraph 1 (Non-payment) and Schedule 2 (Financial undertakings)) to this Term Sheet. |
(b) | No Event of Default under paragraph 3(a) will occur if the failure to comply is capable of remedy and is remedied within 15 Business Days, of the earlier of (A) the Agent giving notice to the Borrower and (B) the Borrower becoming aware of the failure to comply. |
4. | Misrepresentation |
5. | Cross default |
(a) | Any Financial Indebtedness of the Borrower or any Material Subsidiary is not paid when due nor within any originally applicable grace period. |
(b) | Any Financial Indebtedness of the Borrower or any Material Subsidiary is declared to be or otherwise becomes due and payable prior to its specified maturity as a result of an event of default (however described). |
(c) | Any commitment for any Financial Indebtedness of any member the Borrower or any Material Subsidiary is cancelled or suspended by a creditor of the Borrower or any Material Subsidiary as a result of an event of default (however described). |
(d) | Any creditor of any member of the Group becomes entitled to declare any Financial Indebtedness of any member of the Group due and payable prior to its specified maturity as a result of an event of default. |
(e) | No Event of Default will occur under this paragraph 5 if the aggregate amount of Financial Indebtedness or commitment for Financial Indebtedness falling within paragraphs 5(a) to 5(d) is less than USD 7,500,000 (or its equivalent in any other currency or currencies). |
6. | Insolvency |
(a) | The Borrower or any Material Subsidiary: |
(i) | is unable or admits inability to pay its debts as they fall due; |
(ii) | suspends making payments on any of its debts; or |
(iii) | by reason of actual or anticipated financial difficulties, commences negotiations with one or more of its creditors (excluding the Lenders) with a view to rescheduling any of its indebtedness. |
(b) | The value of the assets of any the Borrower or any Material Subsidiary is less than its liabilities (taking into account contingent and prospective liabilities). |
(c) | A moratorium is declared in respect of any indebtedness of the Borrower or any Material Subsidiary. |
7. | Insolvency proceedings |
(a) | Any corporate action, legal proceedings or other procedure or step is taken in relation to: |
(i) | the suspension of payments, a moratorium of any indebtedness, winding‑up, dissolution, administration or reorganisation (by way of voluntary arrangement, scheme of arrangement or otherwise) of the Borrower or any Material Subsidiary other than a solvent liquidation or reorganisation of any Material Subsidiary; |
(ii) | a composition, compromise, assignment or arrangement with any creditor of the Borrower or any Material Subsidiary; |
(iii) | the appointment of a liquidator (other than in respect of a solvent liquidation of a Material Subsidiary), receiver, administrative receiver, administrator, compulsory manager or other similar officer in respect of the Borrower or any Material Subsidiary or any of its assets; or |
(iv) | enforcement of any Security over any assets of the Borrower or any Material Subsidiary, |
(b) | This paragraph 7 shall not apply to any winding‑up petition which is frivolous or vexatious and is discharged, stayed or dismissed within 10 Business Days of commencement. |
8. | Creditors' process |
9. | Unlawfulness and invalidity |
(a) | It is or becomes unlawful for the Borrower to perform any of its obligations under the Finance Documents. |
(b) | Any obligation or obligations of the Borrower under any Finance Documents are not (subject to the Legal Reservations) or cease to be legal, valid, binding or enforceable. |
(c) | Any Finance Document ceases to be in full force. |
10. | Cessation of business |
11. | Change of ownership |
12. | Audit qualification |
13. | Expropriation |
14. | Repudiation and rescission of agreements |
15. | Litigation |
16. | Material adverse change |
1. | The Company |
(a) | A copy of the constitutional documents of the Company. |
(b) | A copy of a resolution of the board of directors of the Company: |
(i) | approving the terms of, and the transactions contemplated by, the Finance Documents and resolving that it execute the Finance Documents; |
(ii) | authorising a specified person or persons to execute the Finance Documents on its behalf; and |
(iii) | authorising a specified person or persons, on its behalf, to sign and/or despatch all documents and notices (including, if relevant, any Utilisation Request) to be signed and/or despatched by it under or in connection with the Finance Documents. |
(c) | A specimen of the signature of each person authorised by the resolution referred to in paragraph 1(b). |
(d) | A certificate of the Company (signed by an authorised signatory) confirming that borrowing the Commitment would not cause any borrowing or similar limit binding on it to be exceeded. |
(e) | A certificate of an authorised signatory of the Company certifying that each copy document relating to it specified in this Schedule 5 is correct, complete and in full force and effect as at a date no earlier than the date of this Agreement. |
2. | Legal opinion |
3. | Other documents and evidence |
(a) | The Original Financial Statements of the Group. |
(b) | Evidence that the fees, costs and expenses then due from the Company pursuant to have been paid or will be paid by the first Utilisation Date. |
(c) | Evidence of satisfaction of any customary or required “know your customer” checks or other similar checks under all applicable laws and regulations in respect of the Company. |
(d) | Evidence that the USD70,000,000 revolving facility made available to the Company pursuant to an amendment and restatement agreement dated 10 April 2018 between the Company as borrower and Barclays Bank PLC as lender will be irrevocably and unconditionally repaid (and permanently cancelled) in full on or before the first Utilisation Date. |
(a) | air (including, without limitation, air within natural or man‑made structures, whether above or below ground); |
(b) | water (including, without limitation, territorial, coastal and inland waters, water under or within land and water in drains and sewers); and |
(c) | land (including, without limitation, land under water); |
(a) | the pollution or protection of the Environment; |
(b) | the conditions of the workplace; or |
(c) | the generation, handling, storage, use, release or spillage of any substance which, alone or in combination with any other, is capable of causing harm to the Environment, including, without limitation, any waste; |
(a) | any counter‑indemnity obligation in respect of a performance or similar bond guaranteeing performance by a member of the Group under any public tender or other contract entered into in the ordinary course of trade; or |
(b) | any guarantee or indemnity granted or arising under legislation relating to tax or corporate law under which any member of the Group assumes general liability for the obligations of another member of the Group; |
(a) | any patents, trade marks, service marks, designs, business names, copyrights, database rights, design rights, domain names, moral rights, inventions, confidential information, knowhow and other intellectual property rights and interests (which may now or in the future subsist), whether registered or unregistered; and |
(b) | the benefit of all applications and rights to use such assets of each member of the Group (which may now or in the future subsist). |
(a) | the principle that equitable remedies may be granted or refused at the discretion of a court and the limitation of enforcement by laws relating to insolvency, reorganisation and other laws generally affecting the rights of creditors; |
(b) | the time barring of claims under the Limitation Acts, the possibility that an undertaking to assume liability for or indemnify a person against non‑payment of UK stamp duty may be void and defences of set‑off or counterclaim; |
(c) | similar principles, rights and defences under the laws of any jurisdiction in which the Borrower conducts its business; and |
(d) | any other matters which are set out as qualifications or reservations as to matters of law of general application specifically referred to in any legal opinion referred to in Schedule 5 (Conditions Precedent) to this Term Sheet; |
(a) | the business, operations, property or financial condition of the Group taken as a whole; or |
(b) | the ability of the Borrower to perform its payment obligations under the Finance Documents and/or its obligations under Schedule 2 (Financial Undertakings) to this Term Sheet; or |
(c) | the validity or enforceability of the Finance Documents or the rights or remedies of any Finance Party under any of the Finance Documents; |
(a) | is listed in Schedule 7 (Material Companies) to this Term Sheet; or |
(b) | has an operating profit representing 10 per cent or more of the consolidated operating profit of the Group (determined in accordance with US GAAP) or has turnover (excluding intra‑group items) representing 10 per cent, or more of the turnover of the Group, calculated on a consolidated basis. |
(a) | a Permitted Share Buyback; |
(b) | an acquisition for cash consideration of all or the majority of the issued share capital of a limited liability company, but only if: |
(i) | no Event of Default is continuing on the closing date for the acquisition or would occur as a result of the acquisition; |
(ii) | the acquired company, business or undertaking is engaged in a business substantially the same as (or ancillary or related to) that carried on by the Group; |
(iii) | the consideration (including associated costs and expenses) for the acquisition and any Financial Indebtedness or other assumed actual or contingent liability, remaining in the acquired company (or any such business) at the date of acquisition (the "Individual Purchase Price") when aggregated with the consideration (including associated costs and expenses) for any other acquisition permitted under this Agreement and any Financial Indebtedness or other assumed actual or contingent liability, remaining in any such acquired companies or businesses at the time of acquisition (the "Total Purchase Price")) does not exceed USD 280,000,000 or its equivalent in aggregate over the life of the Facility. |
(a) | any guarantee comprising a netting or set‑off arrangements entered into by any member of the Group in the ordinary course of its banking arrangements for the purpose of netting debit and credit balances; |
(b) | any indemnity given in the ordinary course of the documentation of an acquisition which is a Permitted Acquisition which indemnity is in a customary form and subject to customary limitations; |
(c) | the guarantee of any Financial Indebtedness permitted by this Agreement; or |
(d) | any Excluded Guarantee; |
(a) | to another member of the Group; or |
(b) | to any other entity (i) in which a member of the Group holds a beneficial interest and (ii) which carries on the same or substantially similar business to the Group, provided such Financial Indebtedness or loans are approved by the board of directors of the Borrower and, in aggregate for those made in any financial year, do not exceed USD 50,000,000 or its equivalent; |
(a) | any factoring programme with recourse (pro solvendo) or without recourse (pro soluto) of receivables of the Group which is in existence at the date hereof; |
(b) | any securitisation and/or factoring programme of the receivables of the Group consented to by Agent (acting on the instructions of the Majority Lenders (acting reasonably)); and/or |
(c) | any disposal of receivables not otherwise permitted under paragraphs (a) or (b) above where the net consideration receivable (when aggregated with the consideration for all such other receivables disposed of) does not exceed USD 40,000,000 in any financial year; |
(a) | any Security listed in Schedule 8 (Existing Security) to this Term Sheet except to the extent the principal amount secured by that Security exceeds the amount stated in that schedule; |
(b) | any netting or set‑off arrangement entered into by any member of the Group in the ordinary course of its banking arrangements for the purpose of netting debit and credit balances; |
(c) | any payment or close out netting or set‑off arrangement pursuant to any hedging transaction entered into by a member of the Group for the purpose of: |
(i) | hedging any risk to which any member of the Group is exposed in its ordinary course of trading; or |
(ii) | its interest rate or currency management operations which are carried out in the ordinary course of business and for non‑speculative purposes only, |
(d) | any lien arising by operation of law and in the ordinary course of trading; |
(e) | any Security over or affecting any asset acquired by a member of the Group after the date of this Agreement if: |
(i) | the Security was not created in contemplation of the acquisition of that asset by a member of the Group; |
(ii) | the principal amount secured has not been increased in contemplation of or since the acquisition of that asset by a member of the Group; and |
(iii) | the Security is removed or discharged within two months of the date of acquisition of such asset; |
(f) | any Security over or affecting any asset of any company which becomes a member of the Group after the date of this Agreement, where the Security is created prior to the date on which that company becomes a member of the Group, if: |
(i) | the Security was not created in contemplation of the acquisition of that company; |
(ii) | the principal amount secured has not increased in contemplation of or since the acquisition of that company; and |
(iii) | the Security is removed or discharged within two months of that company becoming a member of the Group; |
(g) | any Security arising under any retention of title, hire purchase or conditional sale arrangement or arrangements having similar effect in respect of goods supplied to a member of the Group in the ordinary course of trading and on the supplier's standard or usual terms and not arising as a result of any default or omission by any member of the Group; or |
(h) | any Security securing indebtedness the principal amount of which (when aggregated with the principal amount of any other indebtedness which has the benefit of Security given by any member of the Group other than any permitted under paragraphs (a) to (g) above) does not exceed USD 15,000,000 (or its equivalent in another currency or currencies); |
(a) | a merger between the Borrower and any Subsidiary that is consolidated within the consolidated financial statements of the Borrower, provided that the Borrower is the surviving entity; |
(b) | any solvent amalgamation or merger among members of the Group which are not the Borrower; or |
(c) | the solvent liquidation or reorganisation of any member of the Group which is not the Borrower so long as any payments or assets distributed as a result of such liquidation or reorganization are distributed to other members of the Group; |
(a) | listed on, or owned or controlled by a person listed on, a Sanctions List, or a person acting on behalf of such a person; |
(b) | located in or organised under the laws of a country or territory that is the subject of country‑wide or territory‑wide Sanctions, or a person who is owned or controlled by, or acting on behalf of such a person; or |
(c) | otherwise a subject of Sanctions; |
(a) | the United Nations; |
(b) | the United States of America; |
(c) | the European Union; |
(d) | the United Kingdom of Great Britain and Northern Ireland; and |
(e) | the governments and official institutions or agencies of any of paragraphs (a) to (d) above, including OFAC, the US Department of State, and Her Majesty's Treasury; |
(a) | which is controlled, directly or indirectly, by the first mentioned company or corporation; |
(b) | more than half the issued share capital (which gives rise to voting rights) of which is beneficially owner, directly or indirectly, by the first mentioned company or corporation; or |
(c) | with is a Subsidiary of another Subsidiary of the first mentioned company or corporation, |
GROUP MEMBER | SECURITY | TOTAL PRINCIPAL AMOUNT OF INDEBTEDNESS SECURED |
Sorin Group Italia Srl | Mortgage | €210,526 |
Sorin Group Italia Srl | Mortgage | €325,926 |
1. | DEFINITIONS AND INTERPRETATION |
1.1 | Definitions |
“Basic Salary” | means the salary, as specified in Clause 6.1.1 or, as appropriate, the reviewed annual salary from time to time; |
“Board” | means the Board of directors of the Company from time to time or any duly authorised committee thereof, or where the relevant powers have been reserved to the Company’s members, its members from time to time; |
“Compensation Committee” | means the compensation committee appointed by the Board; |
“Confidential Information” | means all information which is identified or treated by the Company or any Group Company or any of the Group’s clients or customers as confidential or which by reason of its character or the circumstances or manner of its disclosure is evidently confidential including (without prejudice to the foregoing generality) any information about the personal affairs of any of the directors (or their families) of the Company or any Group Company, business plans, proposals relating to the acquisition or disposal of a company or business or proposed expansion or contraction of activities, maturing new business opportunities, research and development projects, designs, secret processes, trade secrets, product or services development and formulae, know-how, inventions, sales statistics and forecasts, marketing strategies and plans, costs, profit and loss and other financial information (save to the extent published in audited accounts), prices and discount structures and the names, addresses and contact and other details of: (a) employees and their terms of employment; (b) customers and potential customers, their requirements and their terms of business with the Company/Group; and (c) suppliers and potential suppliers and their terms of business (all whether or not recorded in writing or in electronic or other format); |
“Employment” | means the employment of the Executive under this Agreement or, as the context requires, the duration of that employment; |
“Group” | means together or separately the Company, any holding company of the Company and any subsidiaries and subsidiary undertakings of the Company or any such holding company (and the words “subsidiary” and “holding company” shall have the meanings given to them in section 1159 of the Companies Act 2006 and “subsidiary undertaking” shall have the meaning given in section 1162 of the Companies Act 2006) from time to time; |
“Group Company” | means any company within the Group; |
“Health Care Scheme” | means the medical expenses insurance, permanent health insurance (“PHI”), critical illness insurance or other healthcare or disability scheme(s) or arrangement(s) as may be provided or introduced from time to time by the Company (at the Company’s discretion) for the benefit of executives in the Group; |
“Intellectual Property Rights” | means any and all existing and future intellectual or industrial property rights in and to any Works (whether registered or unregistered), including all existing and future patents, copyrights, design rights, database rights, trade marks, semiconductor topography rights, plant varieties rights, internet rights/domain names, know-how and any and all applications for any of the foregoing and any and all rights to apply for any of the foregoing in and to any Works; |
“Minority Holder” | means a person who either solely or jointly holds (directly or through nominees) any shares or loan capital in any company whose shares are listed or dealt in on a recognised investment exchange (as that term is defined by section 285 Financial Services and Markets Act 2000) provided that such holding does not, when aggregated with any shares or loan capital held by the Executive’s partner and/or his or his partner’s children under the age of 18, exceed 3% of the shares or loan capital of the class concerned for the time being issued; |
“Share Incentives” | means any options or other rights that the Executive may have to purchase, hold or otherwise acquire shares or rights in respect of or relating to shares in the Company or a Group Company; |
“Termination Date” | means the date of termination of the Employment; |
“Works” | means any documents, materials, models, designs, drawings, processes, inventions, formulae, computer coding, methodologies, know-how, Confidential Information or other work, performed made, created, devised, developed or discovered by the Executive in the course of the Employment (and whether or not made or discovered in the course of the Employment) either alone or with any other person in connection with or in any way affecting or relating to the business of the Company or any Group Company or capable of being used or adapted for use therein or in connection therewith. |
1.2 | Interpretation and Construction |
(a) | words importing the singular shall include the plural and vice versa; |
(b) | words importing any gender shall include all other genders; |
(c) | words importing the whole shall be treated as including reference to any part of the whole; |
(d) | any reference to a Clause, the Schedule or part of the Schedule is to the relevant Clause, Schedule or part of the Schedule of or to this Agreement unless otherwise specified; |
(e) | reference to this Agreement or to any other document is a reference to this Agreement or to that other document as modified, amended, varied, supplemented, assigned, novated or replaced from time to time; |
(f) | reference to a provision of law is a reference to that provision as extended, applied, amended, consolidated or re-enacted or as the application thereof is modified from time to time and shall be construed as including reference to any order, instrument, regulation or other subordinate legislation from time to time made under it; |
(g) | references to a “person” includes any individual, firm, company, corporation, body corporate, government, state or agency of state, trust or foundation, or any association, partnership or unincorporated body (whether or not having separate legal personality) or two or more of the foregoing; |
(h) | general words shall not be given a restrictive meaning because they are followed by words which are particular examples of the acts, matters or things covered by the general words and “including”, “include” and “in particular” shall be construed without limitation; and |
(i) | the meaning of any words coming after “other” or “otherwise” shall not be constrained by the meaning of any words coming before “other” or “otherwise where a wider construction is possible. |
1.3 | Headings |
2. | THE EMPLOYMENT |
2.1 | Appointment |
2.2 | Work Permits and warranty |
2.2.1 | The Executive warrants to the Company that by virtue of entering into this Agreement he will not be in breach of any express or implied obligation to any third party, including any restrictive covenants. |
2.2.2 | This employment contract is executed under the condition that the employee obtains all legally required immigration documents, including the residence permit and work permit/visa. |
2.2.3 | As from the commencement of this employment contract, and therefore after receiving all necessary immigration documents, the Executive warrants that he will notify the Company in advance of any possible change to his immigration status, as soon as he becomes aware of any |
3. | DURATION OF THE EMPLOYMENT |
3.1 | Continuous Employment |
3.1.1 | The Executive’s continuous period of employment with the Company commenced on the Effective Date. |
3.1.2 | No employment with any previous employer shall count as part of the Executive’s continuous period of employment. |
3.2 | Duration and Notice |
(a) | the Company, which must give to the Executive not less than six months’ prior written notice of termination of the Employment; or |
(b) | the Executive, who must give to the Company not less than six months’ prior written notice of termination of the Employment. |
3.3 | Payment in lieu of notice |
3.3.1 | The Company shall be entitled, at its sole discretion, to terminate the Employment immediately at any time by giving the Executive notice in writing. In these circumstances, subject to the terms of Clause 3.3.2, the Company will subsequently make a payment to the Executive in lieu of notice, calculated in accordance with the provisions of Clauses 3.3.3 and 3.3.4 (the payment being referred to as a “Notice Payment”). |
3.3.2 | For the avoidance of doubt, the Company is not obliged to make a Notice Payment. If the Company shall decide not to make a Notice Payment, the Executive shall not be entitled to enforce that payment as a contractual debt nor as liquidated damages. |
3.3.3 | The Notice Payment will be paid less all deductions that are required or permitted by law to be made including in respect of income tax, national insurance contributions and any sums due to the Company or any Group Company. |
3.3.4 | Subject to the terms of Clause 3.4, the Notice Payment will consist of a sum equivalent to the Basic Salary which the Executive would have received in respect of any notice period outstanding on the Termination Date, but will exclude any bonus, commission share of profit, pension contributions and any other benefits (including any benefits derived from any Share Incentives) that he would have received or would have accrued to him during that period. |
3.3.5 | The Notice Payment is in full and final settlement of all and any rights and claims that the Executive may have against the Company arising out of the termination of his employment (including both contractual and statutory employment claims). The Executive agrees to waive, release and discharge any and all such rights and claims and acknowledges that it is a condition of the payment of the Notice Payment that he will execute a settlement agreement (and any other |
3.4 | Payment in instalments |
3.4.1 | The Company may, at its sole discretion and subject to the terms of Clause 3.4.2, pay the Notice Payment in equal monthly instalments over a period of six months (the “Instalment Period”), the first instalment payable at the end of the month in which the Termination Date occurs. |
3.4.2 | If the Executive commences alternative employment during the Instalment Period then the gross instalments of Notice Payment payable after that date will be reduced by a sum equal to the gross amount of the Executive’s income from the alternative employment. |
3.4.3 | If the Executive obtains alternative employment that is to commence during the Instalment Period he will immediately advise the Company of that fact and of his gross monthly salary from that employment. If the Executive fails to comply with this obligation, then from the date the Executive commences alternative employment, the Executive shall have no further entitlement to any payment of Notice Payment. |
4. | HOURS AND PLACE OF WORK |
4.1 | Hours of work |
4.2 | Working Time Regulations |
4.2.1 | The Executive has autonomous decision making powers. The duration of his working time is not measured or predetermined. |
4.3 | Place of work |
4.3.1 | The Executive’s place of work will initially be at the Company’s offices at 20 Eastbourne Terrace, W2 6LG London but the Company may require the Executive to work at any other location within or outside the UK for such periods as the Company may from time to time require. The Executive will be given reasonable notice of any change in his permanent place of work. |
4.3.2 | The Executive will not be required to be absent from the United Kingdom for a period exceeding one month at any one time. |
5. | SCOPE OF THE EMPLOYMENT |
5.1 | Duties of the Executive |
(a) | undertake and carry out to the best of his ability such duties and exercise such powers in relation to the Group’s business as may from time to time be assigned to or vested in him, including where those duties require the Executive to work for any Group Company; |
(b) | in the discharge of those duties and the exercise of those powers observe and comply with all lawful resolutions, regulations and directions from time to time made by, or under the authority of, the Board and promptly upon request, give a full account to the Chief Executive Officer of all matters with which he is involved. He will provide the information in writing if requested; |
(c) | comply with the Articles of Association (as amended from time to time) of any Group Company of which he is a director; |
(d) | do, or refrain from doing, such things as are necessary or expedient to ensure compliance by himself and any Group Company with applicable law and regulations; |
(e) | ensure compliance with the UK Corporate Governance Code, as applicable from time to time; |
(f) | act in accordance with all statutory, fiduciary and common law duties that he owes to the Company and any Group Company; |
(g) | refrain from doing anything which would cause him to be disqualified from acting as a director; |
(h) | do, or refrain from doing, such things as are necessary or expedient to ensure compliance by himself and any Group Company with applicable law and regulations and all other regulatory authorities relevant to any Group Company and any codes of practice issued by any Group Company (as amended from time to time); |
(i) | unless prevented by ill-health, holidays or other unavoidable cause, devote the whole of his working time, attention and skill to the discharge of his duties under this Agreement; |
(j) | faithfully and diligently perform his duties and at all times use his best endeavours to promote and protect the interests of the Group; |
(k) | promptly disclose to the Company full details of any wrongdoing by the Executive or any other employee of any Group Company where that wrongdoing is material to that employee’s employment by the relevant company or to the interests or reputation of any Group Company; |
(l) | not incur on behalf of the Company or any Group Company any capital expenditure in excess of such sum as may be authorised from time to time by resolution of the Board; and |
(m) | not enter into on behalf of the Company or any Group Company any commitment, contract or arrangement which is otherwise than in the normal course of the Company's or the relevant Group Company's business or is outside the scope of his normal duties or authorisations or is of an unusual or onerous or long-term nature. |
5.2 | Directorships and Directors and Officers insurance |
5.3 | Right to suspend duties and powers |
5.3.1 | The Company reserves the right in its absolute discretion to suspend all or any of the Executive’s duties and powers on terms it considers expedient or to require him to perform only such duties, specific projects or tasks as are assigned to him expressly by the Company (including the duties of another position of equivalent status) in any case for such period or periods and at such place or places (including, without limitation, the Executive’s home) as the Company in its absolute discretion deems necessary (the “Garden Leave”). During any period of Garden Leave the terms and conditions set out in this Agreement shall continue to apply to the Executive. |
5.3.2 | The Company may, at its sole discretion, require that during the Garden Leave the Executive shall not: |
(a) | enter or attend the premises of the Company or any Group Company; |
(b) | contact or have any communication with any client or prospective client or supplier of the Company or any Group Company in relation to the business of the Company or any Group Company; |
(c) | contact or have any communication with any employee, officer, director, agent or consultant of the Company or any Group Company in relation to the business of the Company or any Group Company; |
(d) | remain or become involved in any aspect of the business of the Company or any Group Company except as required by such companies; or |
(e) | work either on his own account or on behalf of any other person. |
5.3.3 | During Garden Leave, the Executive will continue to receive his Basic Salary and benefits but will not accrue any bonus, commission or share of profit. |
5.3.4 | For the avoidance of doubt, the Company may exercise its powers under this Clause 5.3 at any time during the Employment on a condition that notice of termination has been given by either party. |
6. | REMUNERATION |
6.1 | Basic Salary |
6.1.1 | During the Employment the Company shall pay the Executive a Basic Salary of not less than £280,000 per annum. The Basic Salary shall accrue from day to day and be payable by credit transfer in equal monthly instalments in arrears on or around the last day of each calendar month or otherwise as arranged from time to time. |
6.1.2 | The Basic Salary shall be inclusive of all directors’ fees (if any) to which the Executive may become entitled including all remuneration and director’s fees in respect of services rendered by the Executive to any Group Company. |
6.2 | Salary review |
6.3 | Discretionary bonus |
6.3.1 | The Company may, at its sole discretion, pay the Executive a bonus in respect of each financial year of the Company (the “Bonus”). The Executive’s target bonus is a sum equal to 40% of his Basic Salary for that financial year. The terms and amount of this bonus (and whether it is paid in cash or in other forms, such as shares or share options) will be approved from time to time and notified to the Executive by the Company, or if applicable to the Executive, the Compensation Committee, in its sole discretion. |
6.3.2 | The actual amount of any Bonus payable will be determined by reference to the achievement of performance objectives, which may include both Company and personal performance objectives. The Compensation Committee, if applicable to the Executive, will determine appropriate Company performance targets at the beginning of each financial year. The Bonus will be paid |
6.3.3 | The Bonus will only be paid if the Executive is in Employment (and has not received or served notice of termination of employment) at the date the Bonus is due for payment. Upon the termination of the Executive’s employment or (if earlier) upon either party giving notice under Clause 3 or the Company exercising its rights under Clause 17, the Executive will have no rights as a result of this Agreement or any alleged breach of it to any compensation under or in respect of any Bonus. For the avoidance of doubt, the Bonus will not accrue, nor will the Executive have any legitimate expectation as to the size or form of the Bonus, until the Company pays it to him. There are no circumstances whether in reliance on express or implied terms or otherwise where the Executive can require pay out of a particular sum or payment in a particular form or claim compensation for loss of such a Bonus. |
6.4 | Signing bonus |
6.5 | Corporate Governance |
7. | EXPENSES |
7.1 | Out-of-pocket expenses |
7.2 | Company credit/charge cards |
8. | DEDUCTIONS |
9. | ALLOWANCES |
9.1 | School Allowance |
9.2 | Company car |
10. | PENSION SCHEME |
10.1 | The Scheme |
10.1.1 | The Executive is eligible to join the Company’s pension scheme (the “Scheme”), subject to its rules in force from time to time. Details of the Scheme are available from the Company. Pursuant to the Scheme, the Company will make an annual contribution to the Scheme in respect of the Executive equal to 15% of the Executive’s monthly gross salary and bonus payments, excluding other payments such as the car allowance. The contribution shall be paid to the Scheme at such time or times during the year as the Company shall decide at its discretion. |
10.1.2 | When the Company becomes subject to the employer duties in the Pensions Act 2008, the Company reserves the right to amend the Executive’s pension arrangements in place in its absolute discretion. The Company will inform the Executive of any changes to his pension arrangements at that time. |
10.1.3 | A copy of the current explanatory booklet giving details of the Scheme is available from the HR department. |
10.1.4 | The Scheme is not a contracted-out scheme for the purposes of the Pension Schemes Act 1993. |
10.2 | Company’s right to amend and terminate |
10.2.1 | The Company may at any time terminate the Scheme or the Executive’s membership of it subject to providing him with membership of an equivalent pension scheme. |
11. | OTHER INSURANCE & BENEFITS |
11.1 | Health Care Scheme |
(a) | the Executive’s (and his family’s participation as applicable) is subject to the Company’s rules regarding eligibility and the rules, terms and conditions of the relevant Scheme, both in force from time to time, copies of which shall be available from Human Resources; |
(b) | the Company reserves the right to terminate the Executive’s (or his family’s, as applicable) or the Company’s participation in any of the Schemes, substitute a new scheme for an existing Scheme and/or alter the level or type of benefits available under any Scheme; |
(c) | if a scheme provider (e.g. an insurance company or pensions provider) refuses for any reason (whether under its own interpretation of the rules, terms and conditions of the relevant insurance policy or otherwise) to accept a claim and/or provide the relevant benefit(s) to the Executive (or his family) under the applicable Scheme, the Company shall not be liable to provide (or compensate the Executive for the loss of) such benefit(s) nor shall it be obliged to take action against the provider to enforce any rights under the Scheme; |
(d) | the fact that the termination of the Employment under Clauses 3 and 17 may result in the Executive or his family ceasing to be eligible to receive or continue to receive benefits under any Scheme does not remove the Company’s right to terminate the Employment; and |
(e) | the Executive’s acceptance of such variations to his terms and conditions of employment as may from time to time be required by the Company. |
11.2 | Payments |
11.2.1 | All payments under the Schemes will be subject to the deductions required by law. |
11.2.2 | Where payments are made under a PHI scheme or critical illness scheme, all other payments or benefits provided to or in respect of the Executive will cease from the start of those payments (if they have not done so already), unless the Company is fully reimbursed by the relevant insurance provider for the cost of providing the benefit. |
11.3 | Medical examinations |
12. | RELOCATION PACKAGE |
12.1 | Relocation allowance |
12.2 | Pre-departure Visits |
12.3 | Two Years of Tax Assistance |
12.4 | Immigration Support |
12.5 | Travel to the new employment country (the United Kingdom) |
12.6 | Temporary Living |
12.7 | Housing |
13. | HOLIDAYS |
13.1 | The holiday year |
13.2 | Annual entitlement |
13.2.1 | The Executive’s annual entitlement to paid holidays is to those public or customary holidays recognised by the Company in any holiday year of which there are eight in total and in addition 24 contractual days holiday. In addition, the Executive shall be entitled to one additional day of holiday per year of continuous service (assessed as at 1st January each year) up to a maximum of five additional days. |
13.2.2 | Entitlement to contractual holidays is accrued pro rata throughout the holiday year. The Executive will be entitled to take public and customary holidays on the days that they are recognised by the Company during the holiday year. |
13.2.3 | The Executive is not entitled to carry any unused holiday entitlement forward to the next holiday year without the permission of the Company. |
13.3 | Holiday entitlement on termination |
13.3.1 | Upon notice of termination of the Employment being served by either party, the Company may require the Executive to take any unused holidays accrued in the holiday year in which the termination takes place at that time during any notice period. Alternatively, the Company may, at its discretion, on termination of the Employment, make a payment in lieu of accrued contractual holiday entitlement. |
13.3.2 | The Executive will be required to make a payment to the Company in respect of any holidays taken in excess of his holiday entitlement accrued at the Termination Date. Any sums so due may be deducted from any money owing to the Executive by the Company. |
14. | ABSENCE |
14.1 | Absence due to sickness or injury |
14.1.1 | If the Executive is absent from work due to sickness or injury he shall: |
(a) | immediately inform the Company of his sickness or injury; and |
(b) | In respect of absence due to sickness, injury or accident that continues for more than 7 consecutive days (including weekends) the Executive must provide the Company with a note of fitness to work stating the reason for the absence. Thereafter notes of fitness to work must be provided to the Company to cover the remainder of the period of continuing sickness absence. |
14.1.2 | Failure to follow the requirements referred to in Clause 13.1.1 may result in disciplinary action and loss of Statutory Sick Pay and/or Company Sick Pay pursuant to Clause 13.2. |
14.2 | Payment of salary during absence |
14.2.1 | Subject to the Executive complying with the terms of Clause 13.1.1, the Company may, at its sole discretion, continue to pay Basic Salary during any period of absence due to sickness or injury for up to a maximum of three months in any period of twelve consecutive months (the twelve-month period being referred to as the “Entitlement Period”) unless the Employment is terminated in terms of Clauses 3 or 17. The first Entitlement Period will begin on the first day of absence and any subsequent Entitlement Period will start on the first day of any absence occurring outside an enduring Entitlement Period. |
14.2.2 | Payment of the Basic Salary in terms of Clause 13.2.1 shall be made less: |
(a) | an amount equivalent to any Statutory Sick Pay payable to the Executive; |
(b) | any sums which may be received by the Executive under any insurance policy effected by the Company; and |
(c) | any other benefits or sums which the Executive receives, such as under a PHI or other insurance scheme, in terms of the Employment or under any relevant legislation. |
14.3 | Absence caused by third party negligence |
(a) | notify the Company immediately of all the relevant circumstances and of any claim, compromise, settlement or judgment made or awarded; and |
(b) | if the Company so requires, refund to it an amount determined by the Company, not exceeding the lesser of: |
(i) | the amount of damages recovered by him in respect of loss of earnings during the period of absence under any compromise, settlement or judgment; and |
(ii) | the sums advanced to him by the Company in respect of the period of incapacity. |
15. | RESTRICTIONS DURING EMPLOYMENT |
15.1 | Disclosure of other interests |
(a) | in any trade, business or occupation whatsoever which is in any way similar to any of those in which the Company or any Group Company is involved; and |
(b) | in any trade, business or occupation carried on by any supplier or customer of the Company or any Group Company whether or not such trade, business or occupation is conducted for profit or gain. |
15.2 | Restrictions on other activities and interests of the Executive |
15.2.1 | During the Employment the Executive shall not at any time, without the prior written consent of the Company, either alone or jointly with any other person, carry on or be directly or indirectly employed, engaged, concerned or interested in any business, prospective business or undertaking other than a Group Company. Nothing contained in this Clause 14.2.1 shall preclude the Executive from being a Minority Holder unless the holding is in a company that is a direct business competitor of the Company or any Group Company in which case, the Executive shall obtain the prior consent of the Company to the acquisition or variation of such holding. |
15.2.2 | If the Executive, with the consent of the Company, accepts any other appointment he must keep the Company accurately informed of the amount of time he spends working under that appointment. |
15.3 | Transactions with the Company |
15.4 | Dealing in securities |
15.5 | Compliance with the code on Corporate Governance |
16. | CONFIDENTIALITY AND COMPANY DOCUMENTS |
16.1 | Restrictions on disclosure and use of Confidential Information |
(a) | divulge or communicate to any person; |
(b) | use for his own purposes or for any purposes other than those of the Company or any Group Company; or |
(c) | through any failure to exercise due care and diligence, cause any unauthorised disclosure of; |
16.2 | Protection of Company documents and materials |
(a) | shall be and remain the property of the Company or the relevant Group Company or client; and |
(b) | shall be handed over by the Executive to the Company or the relevant Group Company or client on demand by the Company and in any event on the termination of the Employment; |
17. | INVENTIONS AND OTHER WORKS |
17.1 | Executive to further interests of the Company |
17.2 | Disclosure and ownership of Works |
17.3 | Protection, registration and vesting of Works |
(a) | apply or join with the Company or any Group Company in applying for any Intellectual Property Rights or other protection or registration (“Protection”) in the United Kingdom and in any other part of the world for, or in relation to, any Works; |
(b) | execute all instruments and do all things necessary for vesting all Intellectual Property Rights or Protection when obtained and all right, title and interest to and in the same absolutely and as sole beneficial owner in the Company or such Group Company or other person as the Company may nominate; and |
(c) | sign and execute any documents and do any acts reasonably required by the Company in connection with any proceedings in respect of any applications and any publication or application for revocation of any Intellectual Property Rights or Protection. |
17.4 | Waiver of rights by the Executive |
(a) | the right conferred by section 77 of that Act to be identified as the author of any such Works; and |
(b) | the right conferred by section 80 of that Act not to have any such Works subjected to derogatory treatment. |
17.5 | Power of Attorney |
17.6 | Statutory rights |
18. | TERMINATION |
18.1 | Termination events |
(a) | if the Executive is guilty of any gross misconduct or behaviour which tends to bring himself or the Company or any Group Company into disrepute; or |
(b) | if the Executive commits any material or persistent breach of this Agreement (in the case of a non-material persistent breach, having been given notice in writing of the breach and a reasonable opportunity to rectify the breach) or fails to comply with any reasonable order or direction of the Company; or |
(c) | if the Executive fails to perform his duties to the reasonable satisfaction of the Company after having been given notice in writing of: (i) the areas of underperformance, and (ii) the improvements in performance that are reasonably required by the Company; and after a reasonable period of time to make the necessary improvements in performance; or |
(d) | if he becomes insolvent or bankrupt or compounds with or grants a trust deed for the benefit of his creditors; or |
(e) | if his behaviour (whether or not in breach of this Agreement) can reasonably be regarded as materially prejudicial to the interests of the Company or any Group Company, including if he is found guilty of any criminal offence punishable by imprisonment (whether or not such sentence is actually imposed); or |
(f) | if he has an order made against him disqualifying him from acting as a company director; or |
(g) | if he becomes of unsound mind; or |
(h) | if the Executive is found guilty of a serious breach of the rules or regulations as amended from time to time of the UK Listing Authority (including the Model Code for transactions in securities by directors), or any other regulatory authority relevant to the Company or any Group Company or any code of practice issued by the Company or any Group Company (as amended from time to time); or |
(i) | the expiration of 3 months following notice in writing if the Executive has been prevented by reason of ill health, injury or some other reason beyond his control from performing his duties under this Agreement for a period or periods aggregating at least ninety days in the preceding period of twenty-four consecutive months, provided that if at any time during the period of such notice and before the termination of the Employment the Executive shall provide a medical certificate satisfactory to the Company to the effect that he has fully recovered his physical and/or mental health and that no recurrence of illness or incapacity can reasonably be anticipated, the Company shall withdraw the notice. |
18.2 | Company’s right to proceed |
18.3 | Termination on resignation as director |
18.4 | No damages or payment in lieu of notice |
19. | EVENTS UPON TERMINATION |
19.1 | Obligations upon termination |
(a) | deliver to the Company all Works, materials within the scope of Clause 15.2 and all other materials and property including credit or charge cards, mobile telephone, computer equipment, disks and software, passwords, encryption keys or the like, keys, security pass, letters, stationery, documents, files, films, records, reports, plans and papers (in whatever format including electronic) and all copies thereof used in or relating to the business of the Company or the Group which are in the possession of or under the control of the Executive; |
(b) | resign (without claim for compensation) as a director and from all other offices held by him in the Company or any Group Company or otherwise by virtue of the Employment. For the avoidance of doubt, such resignations shall be without prejudice to any claims |
(c) | transfer without payment, to the Company, or as the Company may direct, any shares or other securities held by the Executive as nominee or trustee for the Company or any Group Company; |
20. | 2RESTRICTIONS AFTER TERMINATION |
20.1 | Definitions |
“Customer” | means any person to which the Company distributed, sold or supplied Restricted Products or Restricted Services during the Relevant Period and with which, during that period either the Executive, or any employee under the direct or indirect supervision of the Executive, had material dealings in the course of the Employment, but always excluding therefrom, any division, branch or office of such person with which the Executive and/or any such employee had no dealings during that period; |
“Prospective Customer” | means any person with which the Company had discussions during the Relevant Period regarding the possible distribution, sale or supply of Restricted Products or Restricted Services and with which during such period the Executive, or any employee who was under the direct or indirect supervision of the Executive, had material dealings in the course of the Employment, but always excluding therefrom any division, branch or office of that person with which the Executive and/or any such employee had no dealings during that period; |
“Relevant Period” | means: (i) where the Employment is continuing, the period of the Employment; and (ii) where the Employment has terminated, the period of twelve months immediately preceding the Termination Date; |
“Restricted Area” | means: (a) the United Kingdom; and (b) any other country in the world where, on the Termination Date, the Company dealt in Restricted Products or Restricted Services; |
“Restricted Employee” | means any person who was a director, employee or consultant of the Company at any time within the Relevant Period who by reason of that position and in particular his seniority and expertise or knowledge of Confidential Information or knowledge of or influence over the clients, customers or contacts of the Company is likely to cause damage to the Company if he were to leave the employment of the Company and become employed by a competitor of the Company; |
“Restricted Period” | means the period commencing on the Termination Date and, subject to the terms of Clause 19.4, continuing for twelve months; |
“Restricted Products” | means any product, device, equipment or machinery researched into, developed, manufactured, supplied, marketed, distributed or sold by the Company and with which the duties of the Executive were materially concerned or for which he was responsible during the Relevant Period, or any products, equipment or machinery of the same type or materially similar to those products, equipment or machinery; |
“Restricted Services” | means any services (including but not limited to technical and product support, technical advice and customer services) researched into, developed or supplied by the Company and with which the duties of the Executive were materially concerned or for which he was responsible during the Relevant Period, or any services of the same type or materially similar to those services; |
“Supplier” | means any supplier, agent, distributor or other person who, during the Relevant Period was in the habit of dealing with the Company and with which, during that period, the Executive, or any employee under the direct or indirect supervision of the Executive, had material dealings in the course of the Employment. |
20.2 | Restrictive covenants |
(a) | so as to compete with the Company, solicit business from or canvas any Customer or Prospective Customer in respect of Restricted Products or Restricted Services; |
(b) | so as to compete with the Company, accept orders from, act for or have any business dealings with, any Customer or Prospective Customer in respect of Restricted Products or Restricted Services; |
(c) | within the Restricted Area, be employed or engaged or at all interested (except as a Minority Holder) in that part of a business or person which is involved in the business of researching into, developing, manufacturing, distributing, selling, supplying or otherwise dealing with Restricted Products or Restricted Services, if the business or person is or seeks to be in competition with the Company. For the purposes of this sub-Clause, acts done by the Executive outside the Restricted Area shall nonetheless be deemed to be done within the Restricted Area where their primary purpose is to distribute, sell, supply or otherwise deal with Restricted Products or Restricted Services in the Restricted Area; |
(d) | solicit or induce or endeavour to solicit or induce any person who was a Restricted Employee (and with whom the Executive had dealings during the Relevant Period) to cease working for or providing services to the Company, whether or not any such person would thereby commit a breach of contract; |
(e) | employ or otherwise engage any Restricted Employee in the business of researching into, developing, manufacturing, distributing, selling, supplying or otherwise dealing with Restricted Products or Restricted Services if that business is, or seeks to be, in competition with the Company; or |
(f) | solicit or induce or endeavour to solicit or induce any Supplier to cease to deal with the Company and shall not interfere in any way with any relationship between a Supplier and the Company. |
20.3 | Application of restrictive covenants to other Group Companies |
(a) | acquired knowledge of its products, services, trade secrets or Confidential Information; or |
(b) | had personal dealings with its Customers or Prospective Customers; or |
(c) | supervised directly or indirectly employees having personal dealings with its Customers or Prospective Customers; |
20.4 | Effect of suspension on Restricted Period |
20.5 | Further undertakings |
(a) | during the Employment or after the Termination Date engage in any trade or business or be associated with any person engaged in any trade or business using any trading names used by the Company or any Group Company including the name(s) or incorporating the word(s) “LivaNova”, “Cyberonics” or “Sorin”; |
(b) | after the Termination Date make any public statement in relation to the Company or any Group Company or any of their officers or employees; or |
(c) | after the Termination Date represent or otherwise indicate any association or connection with the Company or any Group Company or for the purpose of carrying on or retaining any business represent or otherwise indicate any past association with the Company or any Group Company. |
20.6 | Severance |
21. | RECONSTRUCTION AND AMALGAMATIONS |
22. | DISCIPLINARY AND GRIEVANCE PROCEDURE |
22.1 | Disciplinary procedures and grievance procedures |
22.1.1 | Any disciplinary action taken in connection with the Employment will usually be taken in accordance with the Company’s normal disciplinary procedures (which are workplace rules and not contractually binding) a copy of which is available from Human Resources. |
22.1.2 | If the Executive wishes to obtain redress of any grievance relating to the Employment or is dissatisfied with any reprimand, suspension or other disciplinary step taken by the Company, he should follow the procedures set out in the Company’s grievance policy, a copy of which is available from Human Resources. |
23. | GENERAL |
23.1 | Provisions which survive termination |
23.2 | No collective agreements |
24. | DATA PROTECTION AND PRIVACY |
24.1 | Data Protection |
24.2 | Privacy |
25. | AMENDMENTS, WAIVERS AND REMEDIES |
25.1 | Amendments |
25.2 | Waivers and remedies cumulative |
25.2.1 | The rights of each party under this Agreement: |
(a) | may be exercised as often as necessary; |
(b) | are cumulative and not exclusive of its rights under the general law; and |
(c) | may be waived only in writing and specifically. |
25.2.2 | Delay in exercising or non-exercise of any right is not a waiver of that right. |
25.2.3 | Any right of rescission conferred upon the Company by this Agreement shall be in addition to and without prejudice to all other rights and remedies available to it. |
26. | ENTIRE AGREEMENT |
26.1.1 | This Agreement and the documents referred to in it constitute the entire agreement and understanding of the parties and supersede and extinguish all previous agreements, promises, assurances, warranties, representations and understandings between the parties, whether written or oral, relating to the subject matter of this Agreement. |
26.1.2 | Each party acknowledges that in entering into this Agreement it does not rely on, and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement. |
26.1.3 | Each party agrees that it shall have no claim for innocent or negligent misrepresentation or negligent misstatement based on any statement in this Agreement. |
26.1.4 | Nothing in this Clause shall limit or exclude any liability for fraud. |
27. | NO OUTSTANDING CLAIMS |
28. | SEVERANCE |
(a) | the legality, validity or enforceability in that jurisdiction of any other provisions of this Agreement; or |
(b) | the legality, validity or enforceability in any other jurisdiction of that or any other provision of this Agreement. |
29. | 2NOTICE |
29.1 | Notices and deemed receipt |
(a) | if delivered personally, at the time of delivery; |
(b) | in the case of pre-paid recorded delivery or registered post, 48 hours from the date of posting; |
(c) | in the case of registered airmail, five days from the date of posting; and |
(d) | in the case of fax or email, at the time of transmission; |
30. | GOVERNING LAW AND JURISDICTION |
30.1 | Governing law |
30.2 | Jurisdiction |
EXECUTED as a Deed | _________________________________ |
by LIVANOVA PLC | Elodie Maertens |
Full Name: | _________________________________ |
Address: | _________________________________ |
By Alistair Simpson | _________________________________ |
Signature: | _________________________________ |
Full Name: | _________________________________ |
Address: | _________________________________ |
/s/ DAMIEN MCDONALD | |
Damien McDonald | |
Chief Executive Officer | |
(Principal Executive Officer) |
/s/ THAD HUSTON | |
Thad Huston | |
Chief Financial Officer | |
(Principal Financial Officer) |
/s/ DAMIEN MCDONALD | |
Damien McDonald | |
Chief Executive Officer | |
(Principal Executive Officer) |
/s/ THAD HUSTON | |
Thad Huston | |
Chief Financial Officer | |
(Principal Financial Officer) |